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ABSTRACT
The mammary gland cell growth and differentiation are under the control of both
systemic hormones and locally produced growth factors. Among all these important
hormones and growth factors, estrogen plays a central role in mammary gland development.
The biological function of estrogen is mediated by estrogen receptor α (ERα) and estrogen
receptor β (ERβ). Both ERα and ERβ are expressed in the mammary gland, but with distinct
expression patterns. In the mammary gland, ERα has been proved to be the estrogen
receptor that mediates the mitogenic function of estrogen. However the function of ERβ in
mammary cell proliferation is less understood and there remains some controversy.
Accumulating evidence indicates that ERβ, unlike ERα, is a negative regulator of
mammary epithelial cell proliferation.
In this dissertation, ERα and ERβ were evaluated for their expression patterns in
the mammary gland. In the proestrus phase, ERα was detected in about 20% of mammary
epithelial cells; in the diestrus phase, no ERα staining was detected in the mammary gland.
ERβ was expressed in more than 50% of mammary epithelial cells and ERβ staining was
detected in some stromal cells in the proestrus phase. In the diestrus phase, ERβ staining
cells were very limited and the staining intensity was very weak. These data suggest that
the expression levels of both ERα and ERβ undergo dynamic changes during the estrous
cycle. In the ovariectomised (OVX) rats, both ERα and ERβ were detected in more than
50% of mammary epithelial cells. Compared with the ovary-intact rats, the mammary gland
of the OVX rats showed more cells with ER expression, but the staining intensity was
weaker. Taken together, the expression of ERα and ERβ is regulated by estrogen in normal
mammary gland, while without estrogen stimulation in the OVX rats, more mammary cells
showed ER expression, but at a lower level in these cells.
The effects of ERα and ERβ on mammary cell proliferation were studied by two
different approaches, activation of endogenous ERα and ERβ via selective agonists, and
overexpression of ERα and ERβ via lentiviral infection. In the first approach, we used ERα
and ERβ selective agonists, propylpyrazole-triol (PPT) and diarylpropionitrile (DPN)
respectively, to activate endogenous ERα and ERβ in the OVX rats. We found that ERβ
selective agonist DPN counteracts the proliferative effect of ERα selective agonist PPT in
the mammary gland. In the second approach, ERα and ERβ were ectopically overexpressed
in the mammary gland of mature virgin rats by lentivirus infection. We found that ERβ
overexpression significantly decreased mammary cell proliferation rate in both the
proestrus and diestrus phases, indicating that ERβ, unlike ERα, is a negative regulator for
mammary cell proliferation. Collectively, these data supports that in contrast to ERα, ERβ
activation or overexpression is able to inhibit mammary cell proliferation.
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CHAPTER 1: Introduction
Estrogen
Estrogen, a steroid hormone, is a key regulator of growth and differentiation in a
broad range of systems and tissues, including the reproductive system, the mammary gland,
lung, colon, the central nervous system, and the immune system (Findlay et al. 2001, Hall
et al. 2001). There are three major estrogens in the animal body, estrone, estradiol and
estriol. The predominant estrogen in the body during the reproductive years is 17-estradiol.
Estrone is the primary form of estrogen after menopause (Pascoe 1996). The estriol is only
produced in large amounts during pregnancy (Tulchinsky et al. 1972).

Estrogen Biosynthesis
Estrogen biosynthesis is primarily in ovaries, but also in other tissues at different
physiological stages (Nelson et al. 2001). During pregnancy the placenta produces estrogen
to stimulate uterine growth to support the growing fetus (Siiteri et al. 1966). Estrogens are
also produced in small amounts by other tissues such as the liver, adrenal gland, breast, fat
tissue, skin, bone, and brain (Nelson et al. 2001). The biosynthesis of estrogen from acetate
through cholesterol requires a series of enzymes. The enzyme aromatase (CYP19), also
called estrogen synthetase, is responsible for the key step in the biosynthesis of estrogen.
It is a member of the cytochrome P450 superfamily and is able to aromatize androgens into
estrogens (Ghosh et al. 2009).
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In the ovaries, estrogen is produced by developing follicles and the corpus lutea.
According to the 'two cell, two gonadotropin model', estrogen biosynthesis happens in the
theca and granulosa cells (Millier et al. 1994). Theca cells synthesize androstenedione from
cholesterol. Synthesized androtenedione then moves across the basal membrane into
granulosa cells, where it is converted to estrone or estradiol. The production of estrogen in
the ovaries is stimulated by two gonadotropin hormones, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) (Hadley et al. 2006). LH promotes the production of
androstenedione from cholesterol, by stimulating the 17α-hydroxylase (CYP17) in the
theca cells. FSH stimulates the expression of the cytochrome P450 aromatase in granulosa
cells, which catalyze androgens into estrogens (Millier et al. 1994).
Estrogen biosynthesis in peripheral tissues is different from that in the ovary. The
fat tissue, skin and other peripheral tissues do not contain a full set of steroidogenic
enzymes which convert cholesterol via many steps to estrogen. In these tissues, estrogen
production is dependent on the circulating precursors such as androstenedione and the local
aromatase activity (Nelson et al. 2001). The adipose tissue and skin are the primary sites
of peripheral estrogen biosynthesis in women and men (Hemsell et al. 1974). The
aromatase activity increases significantly with age. The conversion rate of androstenedione
to estrone is about 2 to 4 fold higher in age 60s than in age 20s (Cleland et al. 1985).
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Estrogen Transport and Metabolism
Estrogens, synthesized in the ovaries are transported through blood circulation to
target tissues. In the serum, the majority of estrogens are bound to plasma proteins such as
sex hormone-binding globulin (SHBG) and albumin, and only 2-3% estrogens are in the
free form (Gruber et al. 2002). SHBG proteins have high estrogen binding affinity, and a
small amount of estrogens bind to albumin with low affinity (Anderson 1974, Gruber et al.
2002). Although the level of free estrogens is very low in blood circulation, it is responsible
for the feedback regulation of estrogen production (Kacsoh 2000).
During menstrual cycles, the serum concentration of 17-estradiol production
varies. In follicular phase, the concentration is between 40 – 200pg/ml. The serum
concentration, 250 – 500 pg/ml, reaches the peak in preovulatory phase. The level drops
briefly at ovulation, and rises again during the luteal phase for a second peak (100 – 150
pg/ml). At the end of the luteal phase, the level is lowest (40 -50 pg/ml). In postmenopausal
women, the serum concentration is lower than 20 pg/ml (Gruber et al. 2002).
The half-life of estrogens is about 13-17 hours. Estrogens are eliminated from the
body by metabolic disposition. Most of the oxidative metabolism of estrogens takes place
in the liver, several estrogen-metabolizing cytochromes P450 enzymes can also be found
in other tissues at low or undetectable levels (Zhu et al. 1998). Estrogens are first
metabolized to hormonally inactive (or less active) water-soluble metabolites and then
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excreted into urine and/or feces (Zhu et al. 1998). There are several methods to metabolize
estrogens. Estrogens can form glucuronides and sulfates, which is catalyzed by
glucuronidase and sulfatase respectively (Brooks et al. 1971, Hernandez et al. 1992, Musey
et al. 1997). Estrogens can also be metabolized by P450 hydroxylatase to form multiple
hydroxylated metabolites (Martucci et al. 1993, Zhu et al. 1998). Part of these hydroxylated
metabolites can be further catalyzed to form methoxylated estrogens by catechol-Omethyltransferase (Ball et al. 1980). Metabolic hydroxylation and/or conjugation of
estrogens make them more water soluble and meanwhile dramatically reduce or completely
eliminate their estrogenic activity (Martucci et al. 1993). However, enzymatic Omethylation with fatty acids leads to the formation of lipophilic estrogen metabolites,
which have very long half-life and unique estrogenic activities that are not associated with
classical estrogen receptors (Larner et al. 1985, Vazquez-Alcantara et al. 1989).
Estrogen Receptors

The Discovery of Estrogen Receptors
The nuclear signaling of estrogen is mediated through two types of estrogen
receptors, Estrogen Receptor α (ERα) and Estrogen Receptor  (ER). ERα was discovered
by Elwood Jensen in late 1950s (Jensen 1962) and cloned by Stephen Green in 1986 (Green
et al. 1986). In 1996 the second estrogen receptor ER was identified (Kuiper et al. 1996).

4

The Structure of Estrogen Receptors
The gene of ERα and ER are located on different chromosomes, but share similar
gene structure. ERα is located on the long arm of chromosome 6, while ER is located on
the long arm of chromosome 14 (Green et al. 1986, Kuiper et al. 1996). Both types of
estrogen receptors belong to the nuclear receptor (NR) superfamily of transcription factors
(Heldring et al. 2007).
Estrogen receptors have four functional domains, A/B domain, C domain, D
domain, and E/F domain. The amino-terminal A/B domain involves ligand-independent
activation function (AF1), which interacts with other factors to regulate the transcriptional
activation of target genes (McInerney et al. 1996, Onate et al. 1998, Webb et al. 1998). The
AF1 domain is highly variable between the two types of estrogen receptors (Mosselman et
al. 1996). AF1 domain in ERα is very active in stimulation of target gene expression.
However, the activity of AF1 domain in ER is negligible under the same experiment
condition (Cowley et al. 1999). There is evidence indicating that the different responses to
the same ligand between ERα and ER are due to different structures of AF1 in ERα and
ER (McDonnell et al. 1995, Barkhem et al. 1998). The AF1 domain contains specific
phosphorylation sites that are responsible for ligand-dependent and independent activities
of the estrogen receptors (Arnold et al. 1995, Joel et al. 1998). Serine 104, 106, 118 and
167 in ERα are major phosphorylation sites and are significantly phosphorylated in
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response to two major pathways, the MAPK (Mitogen-Activated Protein Kinases) pathway
and the AKT pathway (Lannigan 2003). The phosphorylation of Ser residues in the AF1
domain affects the recruitment of coactivators and usually enhances estrogen mediated
transcription (Lavinsky et al. 1998, Endoh et al. 1999).
The most conserved C domain between ERα and ER is the DNA binding domain
(DBD). It contains two zinc finger structures that are responsible for receptor dimerization
and DNA recognition and binding (Schwabe et al. 1993). ERα and ER share about 96%
similarity in the amino acid sequences of the DBD (Mosselman et al. 1996). Therefore both
ERα and ER can bind to the estrogen response element (ERE) of estrogen responsive
genes with similar affinity (Kuiper et al. 1996, Ogawa et al. 1998).
The D domain of estrogen receptors is less characterized. It connects the DNA
binding domain and the ligand binding domain, and may also play a role in coregulator
binding and nuclear localization (Bhat et al. 1998).
The E/F domain of estrogen receptors is required for ligand binding, also known as
the ligand binding domain (LBD). ERα and ER share about 55% similarity in the amino
acid sequences in the E/F domain and their tertiary architectures are very similar
(Mosselman et al. 1996). Estrone and estradiol have higher affinity to ERα. However the
phytoestrogen genisterin has higher affinity to ER. Most environmental estrogenic
chemicals have similar binding affinity to ERα and ER (Kuiper 1997, Kuiper et al. 1998).
The E/F domain also has other functions such as interaction with heat shock proteins,
6

receptor dimerization, nuclear localization, and activation function, hence the E/F domain
is also named as AF2 domain (Zhang et al. 2003). The function of the AF2 domain is
determined by the binding of ligands (Danielian et al. 1992, Darimont et al. 1998). The
binding of different ligands induces different conformational changes of the receptor that
are important for the recruitment and interaction of coactivators and corepressors
(McDonnell et al. 1995, Henttu et al. 1997, Shiau et al. 1998). For example, after estrogens
bind to the LBD, the helix 12 in the AF2 domain forms a 3D structure to recruit the
coactivators. In contrast, when raloxifene or 4-OH- tamoxifen binds to the LBD, the helix
12 prevents the coactivator binding by covering the coactivator interaction surface
(Brzozowski et al. 1997). Phosphorylation in the AF2 region also plays an important role
in mediating transcriptional activation. So far the tyrosine 537 is the only phosphorylation
site in the AF2 region, which is involved in the recruitment of c-SRC in a ligand-dependent
manner (Migliaccio et al. 1996, Migliaccio et al. 2000).

The Expression of Estrogen Receptors
ERα and ER are expressed in various tissues with different expression patterns.
High levels of ERα expression can be detected in the classical estrogen target tissues such
as the uterus, mammary gland, placenta, central nervous system, cardiovascular system,
and bone (Zhang et al. 2003). The expression of ERα is either low or undetectable in nonclassical estrogen target tissues, such as the prostate, testes, pineal gland, thyroid gland,
7

adrenal gland, gallbladder, and skin (Zhang et al. 2003). However in some of these nonclassical estrogen target tissues, however, ER is highly expressed (Gustafsson 1999). The
expression of ERα and ER is regulated by estrogens in a tissue and/or cell specific manner.
In certain tissues or cells, estrogens have opposite effects on the expression of ERα and
ER (Khurana et al. 2000, Vladusic et al. 2000, Tena-Sempere et al. 2001). For instance,
in bone mesenchymal stem cells and the adipose tissue, estrogens increase the expression
of ERα but decrease the expression of ER (Anwar et al. 2001, Zhou et al. 2001). In some
other tissues or cells, estrogens only affect one ER but not the other. For example, estrogen
treatment only downregulates ER expression in immature rat uterus and stimulates the
expression of ER in the prostate (Khurana et al. 2000, Zhang et al. 2000).

The Coregulators of Estrogen Receptors
Recruitment of coregulators is required for ER-mediated gene transcription
activity of both estrogen receptors. Coactivators turn on target gene transcription, whereas
corepressors inhibit gene transcription and possibly turn off activated target genes.
Coactivators
Among the coactivators, the steroid receptor coactivator protein, the p300 cyclic
AMP response element binding protein, and the thyroid hormone receptor-associated
protein have the greatest capacity to increase the transcriptional activity of estrogen
receptor (Nilsson et al. 2001).
8

Steroid receptor coactivator (SRC) family includes three members: SRC-1 (also
called p160-1), SRC-2 (also called TIF-2) and SRC-3 (also called AIB1). Three conserved
LXXLL motifs are required for the function of these coactivators (Xu et al. 1999). These
motifs represent the primary docking site to the AF2 domain of estrogen receptors (Leers
et al. 1998). The caboxyl terminal of SRC family members contains two separate
transcription activation domains: AD1 and AD2 (Nilsson et al. 2001). AD1 is responsible
for the recruitment of CBP/p300 coactivators and acetyltransferases. AD2 is involved in
the recruitment of coactivator associated arginine methyltransferase (CARM1) (Chen et al.
1999). The primary function of SRC includes recruitment of chromatin, modification of
enzymatic activities, and regulation of target gene expression (Nilsson et al. 2001). The
important role of the SRC family members in estrogen receptor signaling has been
supported by knockout mouse studies (Xu et al. 1998). Estrogen receptor activation is
heavily affected and severe phenotypes have been observed in estrogen target tissues in
TIF2 (a member of the SRC-1 family) knockout mice (Gehin et al. 2002).
CBP/p300 are considered as general coactivators involved in multiple signaling
pathways. The direct interaction between p300 and estrogen receptors have been reported
by many studies. In the presence of estrogen-ER complex, p300 acts synergistically with
estrogen receptor to enhance estrogen targeted gene transcription, but in the absence of
estrogen-ER, p300 has little effect on gene transcription (Hanstein et al. 1996, Kraus et al.
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1998). The pull-down assay found that mutations in the p300 binding site of ERα and ER
and mutations in the A/B domain lead to a reduction in transactivation (Kobayashi et al.
2000).
The thyroid hormone receptor associated protein (TRAP) coactivator complex
connects estrogen receptor to the basal transcription machinery (Freedman 1999). The
receptor binding subunit (TRAP220) interacts with estrogen receptor through a region
containing LXXLL motifs (Yuan et al. 1998). ERα is less efficient than ERβ in recruiting
the TRAP complex (McKenna et al. 1999).
Corepressors
The corepressors are less characterized compared with the coactivators. There are
four major groups of corepressors based on their interaction mechanism with estrogen
receptors. The corepressors in the first group contain a classical corepressor interaction
motif (CoRNR-box) (Shang et al. 2002). The corepressors in the second group contain an
LXXLL motif and are recruited in an estrogen-dependent manner (Chan et al. 1999, Zhang
et al. 2000, Palijan et al. 2009). The corepressors in the third group contain an interaction
domain outside the LBD (Delage-Mourroux et al. 2000, Mazumdar et al. 2000, Norris et
al. 2002, Georgescu et al. 2005). The last type of corepressors may not directly interact
with estrogen receptors, but rather may be recruited through transcription complexes
(Laherty et al. 1998, Shi et al. 2001, Vo et al. 2001).

10

Mechanisms of Estrogen Action
The biological effects of estrogens are mediated by estrogen receptors through four
pathways: classical ligand dependent pathway, ligand independent pathway, estrogen
response element (ERE) independent pathway, and non-genomic pathway (Hall et al. 2001).

Classical Ligand Dependent Pathway
Estrogen as a steroid hormone can freely diffuse across the cell membrane. In the
absence of estrogen, estrogen receptors are sequestered in a multiprotein inhibitory
complex (Hall et al. 2001). Upon the binding of an estrogen, the receptor undergoes a
conformational change and interacts with another ligand-receptor complex to form a
homodimer or heterodimer. This dimer moves into the nucleus and binds to the promoter
region of a target gene through specific ERE (Pettersson et al. 1997, Nilsson et al. 2001).
The dimer does not only bind to the DNA but also recruits a variety of coregulators to the
receptor (McKenna et al. 1999). These coregulatory proteins interacting with estrogen
receptors are able to alter the chromatin structure and help assemble the RNA polymerase
transcriptional machinery (Heldring et al. 2007).

Ligand Independent Pathway
In addition to hormone mediated activation, estrogen receptor function can also be
modulated without estrogen binding. The general extracellular signals such as growth
factors, cytokines and neurotransmitters can activate intracellular pathways which lead to
11

phosphorylation and activation of estrogen receptors (Rosenfeld et al. 2006). Epidermal
growth factor (EGF) mimics the effect of estrogen action on female reproductive tract and
mammary gland (Ignar-Trowbridge et al. 1992, Curtis et al. 1996, Ankrapp et al. 1998).
Insulin-like growth factor (IGF) and transforming growth factor- (TGF-) are also able
to activate estrogen receptor signaling (Aronica et al. 1993, Ma et al. 1994, Newton et al.
1994, Ignar-Trowbridge et al. 1996). Interleukin-2 (IL-2) and dopamine have been reported
to modulate estrogen receptor activities, although the mechanism is still under investigation
(Power et al. 1991, Smith et al. 1993). Phosphorylation modification of estrogen receptors
has been shown to be an important mechanism of ligand-independent activation (Arnold et
al. 1995, Joel et al. 1998, Lannigan 2003). The kinases in mitogen activated protein kinase
(MAPK), AKT and other signaling pathways are thought to be responsible for these
phosphorylation events (Bunone et al. 1996, Joel et al. 1998, Sun et al. 2001). The serine
118 residue in the AF1 domain is phosphorylated by MAPK, which is activated by EGF or
IGF treatment (Kato 2001). In contrast to MAPK, cAMP activates estrogen receptors
through AF2 domain (El-Tanani et al. 1997).

ERE Independent Pathway
In nonclassical nuclear signaling, the estrogen-ER complex regulates gene
transcription without binding directly to the DNA sequence containing ERE, but through
interacts with other transcription factors such as Nuclear Factor kappa B (NFκB),
12

Specificity Protein 1 (SP1) and Activator Protein-1 (AP-1) (Kushner et al. 2000, Saville et
al. 2000, Liu et al. 2005). ER-NFκB complex prevents NFκB from binding to DNA and
inhibits the expression of cytokine IL-6 (Galien et al. 1997). ERα can activate transcription
of the retinoic acid receptor 1 (RAR1) gene via formation of the ER-SP1 complex at the
RAR1 promoter region (Sun et al. 1998). The activation of IGF-1 is mediated by ERα
through interaction of ERα with c-Fos and Jun at the AP-1 binding site. This activation
requires both the AF-1 and AF-2 domain of ERα (Umayahara et al. 1994). Due to structural
differences in the AF-1 domain of the receptors, ER is unable to activate transcription of
AP-1 regulated genes (Kushner et al. 2000).

Nongenomic Pathway
The classical nuclear action of estrogen takes minutes or hours to increase or
decrease protein synthesis. A number of rapid biological estrogenic effects which happen
in seconds cannot be explained by a transcriptional mechanism. These rapid estrogen
actions are results of direct estrogenic responses on the cell membrane (Simoncini et al.
2004). On the cell membrane, G protein coupled receptors (GPCRs) such as GPR30 have
estrogen binding site. Upon binding with estrogens, GPCRs activate downstream
intercellular signal transduction pathways such as the AKT and MAPK signal pathways in
many cell types, and generate rapid tissue responses (Collins et al. 1999, Sylvia et al. 2000,
Wong et al. 2002, Liu et al. 2009). In endothelial cells, engagement of estrogen receptors
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results in rapid endothelial nitric oxide (NO) release through the AKT pathway (Pyo Kim
et al. 1999, Chambliss et al. 2002). In pancreatic cells, estrogen regulates the K+-ATP
channel activity and activates the rapid insulinotropic effect (Ripoll et al. 2008).

Physiological Action of Estrogens
Estrogens are involved in many physiological processes including growth and
development of the reproductive system, fat deposition, and estrous/menstrual cycle. Most
studies focus on estrogen action on the development of sexual and reproductive systems.

Estrogen Action on the Ovary
Estrogens are mainly produced in the ovary and act on granulosa, theca and luteal
cells in the ovary. Estrogens have pleiotropic effects on granulosa cells including
promoting proliferation, increasing the ER expression and exerting antiatretic effect
(Sherwood et al. 1994, Quirk et al. 2004). In addition, estrogens synergize with
gonadotropins in many processes such as promoting ovarian growth, increasing LH and
FSH receptor expression and regulating aromatase activity (Hadley et al. 2006).
Most studies support that the ovary is a tissue of estrogen action through the
classical ligand dependent pathway (Britt et al. 2002, Jameson et al. 2010). Both estrogen
receptors can be detected in the ovary. ERα is mainly expressed in the theca cells and some
stromal cells; ER is predominantly expressed in the granulosa cells of growing follicles
14

and in some stromal cells as well (Sar et al. 1999, Pelletier et al. 2000, Zhang et al. 2003).
However, the ERα knockout and ER knockout female mice have morphologically normal
ovaries before puberty, indicating that neither ERα nor ER is necessary for the embryonic
development of the ovary (Couse et al. 1999, Cheng et al. 2002, Zhang et al. 2003).
Although estrogens are not essential for the growth of follicles, estrogen action on
granulosa cells and oocytes is required by the orchestration of events that result in a mature
oocyte capable of developing into a viable embryo (Jameson et al. 2010).

Estrogen Action on the Fallopian Tube
Two major types of cells exist in the fallopian tube (oviduct): ciliated cells and
peg cells. Estrogens act on the ciliated cells to promote growth, proliferation, activity and
specializations including ciliogenesis (Shao et al. 2007, Shao et al. 2009). Both ERα and
ER are expressed in the ciliated cells, but ERα serves as the dominant regulator in ciliated
cell development (Mowa et al. 2000, Shao et al. 2007). ER is involved in the regulation
of calcium dependent ciliated beating, which helps the ovum to move from the ovary to the
uterus in the primate (Shao et al. 2007). In other species, the smooth muscle contractions
are more important for the ovum movement, and estrogen and progesterone ratio regulates
the activity of the smooth muscle (Jansen 1984).
Only ERα is detected in peg cells. The peg cells are located between the ciliated
cells, containing apical granules and producing the tubular fluid. The peg cells undergo a
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cycle of hypertrophy and atrophy throughout the estrous cycle. The cell size and secretory
activity of the peg cells increases during the follicle phase, and the release of secretory
granules occurs in the luteal phase (Nilsson et al. 1969, Jansen 1984). The fluid in fallopian
tube supports sperm and oocyte survival, sperm capacitation, and fertilization (Leese 1988).
Through stimulation of ERα, estrogens promote the peg cells to produce and release
proteins and components of intraluminal tubal fluid (Hewitt et al. 2002, Shao et al. 2007,
Buhi et al. 2008).

Estrogen Action on the Uterus
The uterus is one of the major classical estrogen target tissues. It is composed of
several heterogeneous cell types: stromal, luminal epithelial, glandular epithelial and
smooth muscle cells (Lecce et al. 2001). All of these cells undergo dynamic changes of
proliferation, differentiation and apoptosis in response to changes in levels of estrogen and
progesterone, and they work together to support embryo development during pregnancy
(Martin et al. 1973, Tan et al. 1999). The knockout mouse model has shown the essential
role of estrogen in the development of the uterus, but estrogens only stimulate certain types
of cells to proliferate in the uterus (Hewitt et al. 2002). In the immature uterus, estrogen
induces both the stromal and epithelial cells to proliferate, but the proliferation rate is very
low (Martin et al. 1973). In the adult uterus, estrogen only stimulates proliferation of the
epithelial cells (Martin et al. 1973). After pregnancy, estrogen first activates and promotes
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proliferation of the luminal and glandular epithelial cells, and then ceases the proliferation
and stimulates cell differentiation (Dey et al. 1996).
Most of the known effects of estrogen in the uterus are mediated by ERα, which
is the predominant type of estrogen receptor expressed in the uterus (Li 1994). Similar to
the expression in the mammary gland, the expression of ERα in the uterine epithelial cells
decreases after estrogen treatment (Nephew et al. 2000). However, the expression of ERα
in stromal cells is upregulated by estrogen (Nephew et al. 2000). ERα is involved in the
uterotrophic effects of estrogen, and this has been confirmed by the ERα knockout mice
(Lubahn et al. 1993). Cooke and colleagues (1997) showed that ERα mediates the
proliferative effect of estrogen on epithelial cells but the epithelial ERα is not sufficient for
estrogen-induced epithelial cell proliferation. They also proposed a paracrine model in the
uterus that estrogen induction of epithelial cell proliferation is mediated by ERα positive
stromal cells (Cooke et al. 1997).
ER expression is less prominent than that of ERα, but ER can be detected in
epithelial, stromal and glandular cells in the uterus (Matsuzaki et al. 1999, Lecce et al.
2001). In the ER knockout mice, Zhang and colleagues (2000) found enlarged lumen
filled with fluid, increased number of glands, and more proteins detected in uterine
secretion. They also found that the level of proliferation marker Ki67 was elevated. These
results indicate that ER acts as the negative regulator of ERα and has an anti-proliferative
effect in the uterus.
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Estrogen Action on the Cervix
The uterine cervix contains endocervical glands, which are regulated by estrogens.
During the proestrus stage, without high level of estrogen stimulation, small glandular cells
in the cervix release small amount of acidic fluids which can host spermatozoa. In the estrus
stage, high level of estrogens stimulate cell growth, proliferation and secretory activities.
The size and number of glandular cells reach the peak right before ovulation occurs (Jones
et al. 2006). At this time, mucus production increases up to 10 times more than that in
proestrus stage, and the elasticity of mucus, usually referred as spinnbarkeit, is greatly
increased (Gorodeski 1996). However, the mechanism of estrogen regulation in the mucus
production is not clear. One possible mechanism is that estrogens increase the permeability
of cervical epithelium by decreasing the paracellular resistance, leading to increasing
mucus production (Gorodeski 1998). Estrogen is also able to modulate transcellular
movement of water and ion transport, which might lead to increasing mucus production
(Davis et al. 1978, Pragnell et al. 1990).

Estrogen Action on the Vagina
There is growing a number of evidence showing that estrogen is involved in cells
proliferation, stratification, and cornification in vaginal epithelium (Hadley et al.). The
vaginal epithelium is thin and dry when estrogen level is low, such as before puberty, at
menopause or in the OVX mouse (Buchanan et al. 1998). Although ERα is expressed in
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vaginal epithelium, estrogen does not stimulate vaginal epithelial cell proliferation through
ERα in vitro. After the cultured epithelium is transplanted back to vaginal stroma in vivo,
the epithelial mitogenic response to estrogen is re-established, indicating that estrogeninduced cell proliferation is mediated indirectly through stromal ERα (Cooke et al. 1986).
Estrogen-induced differentiation of vaginal epithelium is more complex and
involves differentiation of multiple layers of suprabasal cells (Buchanan et al. 1998). In the
presence of estrogen and progesterone, the suprabasal cells stop proliferating and undergo
a series of differentiation processes. They move up through epithelium, become larger and
undergo structural and morphological changes indicative of cornification, so that the apical
layer becomes heavily keratinized (Buchanan et al. 1998).
Mammalian vaginal epithelium undergoes morphological changes during the
estrous cycle, which are regulated by the estrogen levels in the plasma (Kim et al. 2004).
During early estrus stage, high levels of estrogen promote proliferation of the vaginal
epithelium and the vaginal wall gradually thickens (Jones et al. 2006). In the late estrus,
along with the decrease in estrogen levels, the superficial cells become keratinized, lose
their nuclei and get sloughed off (Kronenverg et al. 1985). In diestrus stage, due to the
absence of estrogens and high progesterone levels, mucification of the epithelium takes
place (Parekkal et al. 1972, Parakkal 1974).
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Effect of Estrogen on the Menstrual Cycle
Menstrual cycle is a complex event which depends on a timely and intricate
interaction between hypothalamus, pituitary gland, ovaries and uterus. There are numerous
direct and indirect, positive and negative, autocrine and paracrine regulation between main
hormones (Pascoe 1996).
Each menstrual cycle can be divided into three main phases: the follicular phase,
luteal phase and menstrual phase (Hadley et al 2006). Estrogens are secreted by follicles in
the ovaries and stimulate the uterine endometrium to proliferate during the follicular phase.
In response to estrogen stimulation, uterine glands begin to enlarge, and the endometrium
becomes more richly supplied with blood vessels. The level of estrogen increases
throughout the follicular phase and reaches the peak at day 12 or 13. Approximately 24 to
48 hours after the peak, rapidly increased LH leads to ovulation (Jones et al. 2006).
Estrogen and other hormones form a complex feedback regulatory network during the
follicular phase. At the beginning of the follicular phase when the estrogen level is low,
the FSH level rises due to the absence of negative feedback regulation by estrogen on
Gonadotropin-releasing hormone (GnRH) which stimulates the secretion of FSH. After
estrogen reaches a moderately high level, it negatively regulates GnRH, and the FSH level
begins to decrease. The estrogen level reaches the peak the end of follicular phase, which
leads to the LH and FSH surge and ovulation (Ferin et al. 1993). After ovulation, the corpus
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luteum is formed from the wall of the follicle and begins to secrete estrogen and
progesterone. Four days before menstruation, the corpus luteum ceases hormone secretion
and the levels of estrogen and progesterone decrease (Jones et al. 2006). Matrix
metalloproteinases are activated by estrogen and progesterone and degrade both interstitial
matrix and basement membranes, resulting in the degeneration of the endometrium and
menstruation (Ferin et al. 1993, Jones et al. 2006).

Estrogen Action in the Male Reproductive System
Estrogen is typically considered as a female hormone, while testosterone is
considered as a male hormone. However, both hormones are present in both male and
female and estrogen plays an important role in the male reproductive system (Lazari et al.
2009). In males, estrogens are produced in peripheral tissues and testis. Leydig cells and
germ cells contain aromatase in adult testis (Hess 2003). Estrogens are present at a very
low level in the blood of males (Ganjam et al. 1976). However, the concentration of
estrogen is extraordinarily high in semen and rete testis fluids, even higher than the average
serum concentration of estrogen in female (Overpeck et al. 1978).
In aromatase knockout mice, loss of estrogen synthesis results in decreased
fertility with aging (Fisher et al. 1998, O’donnell et al. 2001). Low concentrations of
estrogen have been demonstrated to effectively inhibit germ cell apoptosis (Pentikäinen et
al. 2000). Estrogen also regulates the storage and phosphorylation of Fos proteins in germ
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cells (Cobellis et al. 1999, Cobellis et al. 2002). In addition, estrogens have been reported
to regulate differentiation and regeneration of the Leydig cell, sertoli cell function and
sertoli-germ cell adhesion (Abney et al. 1991, MacCalman et al. 1997, McKinnell et al.
2001, O’Donnell et al. 2001).
ERα is detected in Leydig and sertoli cells and mediates the regulatory function of
estrogen in Leydig cells (O’Donnell et al. 2001, Lucas et al. 2008, Strauss et al. 2009). It
has been shown that ERα is not essential in initiating or maintaining spermatogenesis using
ERα knockout mice, and the expression of ERα in germ cells is only detected in some
studies but not others (Mahato et al. 2000, O’Donnell et al. 2001). ER is expressed more
extensively than ERα in testis. ER is not only expressed in Leydig-stertoli cells but also
in spermatogonia and spermatiocytes (Qing et al. 2002). Although ER knockout male
mice have normal testis structure and are fertile, a number of studies suggested that ER
has a potential role in spermatogenesis (Krege et al. 1998, Dupont et al. 2000, Oliveira et
al. 2002, Cho et al. 2003). After long term treatment of ICI (a steroidal estrogen antagonist)
that have directly effects on ERβ, spermatogenesis turns abnormal (Cho et al. 2003).
The highest levels of ERα and ER are expressed in the efferent ductules of the
male reproductive tract, even higher than the uterine tissue, indicating that the efferent
ductules are the major target of estrogen action (Hess et al. 1997, Oliveira et al. 2004). The
efferent ductules transport sperm from the testis to epididymis. The non-ciliated cells in
ductules reabsorb about 90% of the rete testis fluid, therefore the concentration of sperm is
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increased (Chan et al. 1995, Hess et al. 2004). Higher concentration of sperm improves
their survival and maturation during storage and ensures that a large number of sperm are
released per ejaculation (Meisel et al. 1994). The ERα knockout mice and anti-estrogen
drug treated mice produce abnormal sperm and morphologically abnormal efferent
ductules, as well as significantly reduced concentrations of sperm in the epididymis,
suggesting that ERα plays an important role in sperm and efferent ductules development
(Hess et al. 1997, Lee et al. 2001).
Both ERα and ER can be found in epididymis and vas deferens, but the function
of estrogen in epididymis and vas deferens is not fully understood (Qing et al. 2002, Shayu
et al. 2005, Frenette et al. 2009). Estrogen may be important for sperm concentration and
motility in epididymis, and responsible for determining the development of vas deferens
(Meistrich et al. 1975, Atanassova et al. 2005, Karlsson 2006, Motrich et al. 2007).

Estrogen Action in the Brain
Besides the reproductive system in female and male, estrogens also target other
tissues or organs including the brain, blood vessel, bone, lung and colon.
Estrogens have numerous effects on the brain (McEwen et al. 1999). In the
hypothalamic-pituitary-gonadal axis, estrogen acts as a feedback signal to regulate the
activity of the hypothalamus and pituitary to control normal reproductive function (Marieb
et al. 2007). Estrogens also regulate the concentration of neurotransmitters including
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serotonin, dopamine and norepinephrine, which play a key role at brain synapses involved
in mood regulation and cognition (McEwen et al. 1999). Estrogens have also been shown
to protect the neuronal cells by reducing oxidative damage and promoting neuronal
survival (Arimatsu et al. 1986, Mooradian 1993, Green et al. 1997). The loss of estrogen
is thought to contribute to the development of the Alzheimer's disease, which represents a
result of the neuronal injury (Khachaturian 1985, Birge 2000). Another significant effect
of estrogens on the brain is that estrogens can regulate the blood supply in the brain. The
brain represents about 2.5% of body weight, but receives 15% of blood and consumes 20%
of oxygen. Therefore the blood supply regulated by estrogen is critical for maintaining
normal brain function such as cognition and hot flushes, and deficient blood supply caused
by lack of estrogen regulation may increase the risk of brain diseases such as stroke,
Alzheimer's disease and Parkinson's disease (Henderson 2000, Leon et al. 2011).

Estrogen Action in the Cardiovascular System
Both estrogen receptors are found both in vascular smooth muscle cells and
endothelial cells, indicating the important role of estrogen in the cardiovascular system
(Karas et al. 1994, Venkov et al. 1996). The primary function of estrogen in the
cardiovascular system is to protect blood vessels. Estrogen can affect the lipoprotein
metabolism which indirectly protect the cardiovascular system (Stauffer et al. 2000). The
effect of estrogen on vessel wall mediates estrogen’s protective action directly. On one
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hand, estrogen can promote vasodilation by stimulating prostacyclin and nitric oxide
synthesis and release (Wen-Chang et al. 1980, Conrad et al. 1993). On the other hand,
estrogens have an acute inhibitory effect on vascular smooth muscle contraction, mediated
by an rapid effect on Ca2+ mobilization and fluxes (Zhang et al. 1994). Furthermore, at the
cellular level, estrogens regulate smooth muscle cell migration and proliferation, as well as
apoptosis of endothelial cells (Fischer-Dzoga et al. 1983, Spyridopoulos et al. 1997).

Estrogen Action on Bone
Estrogen is an important hormone which regulates bone metabolism in both women
and men. Estrogen affects osteocytes, osteoclasts and osteoblasts, which are responsible
for the bone formation, remodeling, resorption and maintenance (Kleerekoper 2001).
Osteocytes is an important target of estrogen and plays a central role in regulating the
activation of bone remodeling and bone resorption. Estrogen deficiency leads to a four time
increase in osteocytes apoptosis resulting in bone remodeling. (Tomkinson et al. 1997).
Estrogen can increase lifespan of osteoclasts by reducing osteoclast apoptosis, and promote
osteoclast differentiation by regulating receptor activator of NFkB ligand (RANKL)
expression (Shevde et al. 2000, Srivastava et al. 2001). Moreover, estrogen affects
osteoclasts indirectly by negatively regulate production of many bone-resorbing cytokines
which stimulate osteoclast formation and activity (Manolagas et al. 1995, Jilka 1998,
Eghbali-Fatourechi et al. 2003).
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Estrogen Action on the Lung
Estrogen and its receptors also play important roles in regulating growth and
differentiation of the lung tissue. In the pernatal stage, the development of lung is more
rapid in female than male. The neonatal females have higher expiratory flow rates
normalized to size than male neonates (Doershuk et al. 1974). In addition, the adult females
have a higher mass-specific gas exchange surface area and smaller alveoli than the males
(Massaro et al. 1996). These differences between male and female lung development may
be due to both the inhibitory effects of androgen and the stimulatory effects of estrogen
(Ballard 1989). Estrogens have been proved to stimulate lung cell proliferation in normal
lung fibroblast and this proliferated effect can be blocked by fluvestrant (estrogen receptor
antagonist, suggesting that estrogen plays an important role in the development of lung
epithelium and mesenchyme (Omoto et al. 2001). However, the proliferative effect of
estrogen in the lung tissue may increase the risk of lung cancer, suggested by the
epidemiological studies on postmenopausal women receiving hormone replacement
therapy (HRT) (Adami et al. 1989). This has been supported by other studies as well,
suggesting that women have higher risk for developing chronic pulmonary disease and lung
cancer than men (Taioli et al. 1994, Zang et al. 1996, Prescott et al. 1997, Stabile et al.
2004).
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Studies on the presence of ERα in the lung have always been controversial. There
is a study showing that ERα is only expressed in normal lung tissue (Massaro et al. 2007).
Other studies reported that ERα is only expressed in malignant lung epithelial cells (Beattie
et al. 1985, Stabile et al. 2002, Pezzi et al. 2003, Hershberger et al. 2005, Pietras et al.
2005). However, a number of studies found that little or no ERα is expressed in either
normal or cancer tissue of the lung (Matsuda et al. 1993, Ollayos et al. 1994, Brown et al.
1997, Nunno et al. 2000, Patrone et al. 2003, Morani et al. 2008).
Unlike ERα, ERβ has been shown to be expressed in normal lung tissue and most
non-small cell lung cancer (NSCLC) cell lines (Omoto et al. 2001, Mollerup et al. 2002,
Stabile et al. 2002, Stabile et al. 2004). Massaro and colleagues (2007) have reported that
the formation of a full complement of alveoli requires the presence of functional ERβ
(Massaro et al. 2007). Using ERβ knockout mice, ERβ has also been shown to regulate
lung development through platelet derived growth factor A and granulocyte-macrophage
colony stimulating factor (Patrone et al. 2003).

Estrogen Action in the Colon
The effects of estrogens on colon have been reported in a number of in vivo and in
vitro studies, but with conflicting results. Most studies showed that estrogens inhibit cell
proliferation while others demonstrated that estrogens promote the proliferation of colon
cells (Hoff et al. 1980, Xiaomeng et al. 1994, Calle et al. 1995, Newcomb et al. 1995, Di
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Domenico et al. 1996, Franceschi et al. 1998, Rossouw et al. 2002, Anderson et al. 2004).
The studies using ovariectomized mice showed that estrogens inhibit colon epithelail cell
proliferation (Hoff et al. 1979, Hoff et al. 1980, Martineti et al. 2005). The epidemiological
studies suggested that the HRT decreases the incidence of colorectal cancer in
postmenopausal women, which also suggesting the negative effect of estrogen on colon
cell proliferation (Calle et al. 1995, Newcomb et al. 1995, Franceschi et al. 1998, Rossouw
et al. 2002, Anderson et al. 2004). However, Arai and colleagues did not find that estrogens
inhibit or stimulate colon cell proliferation; rather, they found that the colon cells were
poorly responsive to estrogens (Arai et al. 2000).
Conflicting results can also be seen in studies on the expression of ERα. While
some of these studies demonstrated the ERα is expressed in normal colon cells, colon
cancer cell lines and colon tumor tissue (Waliszewski et al. 1997, Foley et al. 2000,
Campbell-Thompson et al. 2001, Weyant et al. 2001), other studies suggested ERα is
absent in colon cancer cells (Issa et al. 1994, Fiorelli et al. 1999, Arai et al. 2000).
ERβ is the predominant ER in the colon tissue and can be detected in both the
normal colon epithelium and colorectal carcinoma (Witte et al. 2001, Martineti et al. 2005).
The functions of ERβ in the colon are not fully understood yet, but several studies have
suggested an inhibitory effect of ERβ on colon cell proliferation. ERβ reduces expression
of cyclin E, a positive proliferation marker, and induces expression of p21, a negative
proliferation marker (Sutter et al. 1996). The expression of ERβ is significantly decreased
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in colon tumors compared with normal colon tissue (Foley et al. 2000, CampbellThompson et al. 2001). Overexpression of ERβ has an anti-proliferative effect throught the
ligand independent pathway (Martineti et al. 2005).
Estrogen Action in the Mammary Gland

Normal Mammary Gland Development
Mammary gland growth is related to age and physiological conditions (Visvader et
al. 2003). The normal mammary gland development can be divided into several distinct
stages, including embryonic, pre-pubertal, pubertal, pregnancy, and lactation.
The mammary gland is derived from the ectoderm and mesoderm layers and
develops into rudimentary ductal bud structures. In the embryonic stage, the mammary
gland is regulated by several signaling molecules and the epithelia-mesenchymal
interaction (Hennighausen et al. 2001). Three pathways, Hedgehog, Notch and Wnt
signaling pathway, are mainly involved in the regulation of mammary gland development
(Clarke et al. 2003, Willert et al. 2003, Liu et al. 2006, van Amerongen et al. 2009). In
addition, several factors have been recognized as key regulators for the initial stage of
mammary gland development, including trans-acting T cell specific transcription (GATA),
nuclear transcription factor kappa B (NFκB), fibroblast growth factor (FGF), bone
morphogentic protein (BMP) and parathyroid hormone related protein (PTHrP)
(Wysolmerski et al. 2001, Kouros-Mehr et al. 2006, Veltmaat et al. 2006, Hens et al. 2007,
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Schramek et al. 2011). PTHrP is the first signaling molecule known to be secreted by
embryonic mammary epithelial cells and responded by surrounding mammary
mesenchymal cells. PTHrP is necessary for the full differentiation of mammary
mesenchyme. In the absence of PTHrP, mesenchymal cells condense around the epithelial
bud and inhibit the mammary bud growth (Wysolmerski et al. 1998, Dunbar et al. 1999,
Foley et al. 2001). Mammary gland development in this stage is independent of estrogen.
High doses of estrogen even lead to a number of abnormalities of mammary development,
including partial inhibition of the mammary bud, formation of a cavity at the site of the
mammary bud, excessive formation of the mesenchyme around the primary mammary duct
(Anderson 1978).
At birth, the mammary gland only contains simple rudimentary ducts and keeps
almost the same structure until puberty (Sinha et al. 1969). In bovine, the mammary gland
grows at the same rate as general body growth (isometric growth) during the first 2-3
months. After 3 months, the growth rate accelerates to about 3.5 times higher than that of
general body growth (allometric growth). Then the growth rate returns to isometric growth
from 9 months to puberty (Sinha et al. 1969). Unlike the embryonic stage, in prepubertal
stage the mammary gland development is hormone dependent. The essential role of
estrogen has been proved by ovariectomized cows (Berry et al. 2003). The proliferation of
mammary epithelial cells is significantly lower in ovariectomized heifers and the mammary
gland size is only one third of normal mammary gland (Berry et al. 2003).
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From infancy to right before puberty, the mammary gland has no big difference
between the female and male. At the beginning of female puberty, due to large increase in
the levels of systemic hormones, the mammary gland undergoes dramatic changes (Pfaff
et al. 1994). In human, this process usually takes 3 to 4 years. Estrogen acts synergistically
with other hormones such as somatotropin and progesterone to regulate mammary gland
growth during this stage (Ruan et al. 1995, Brisken et al. 1998, Silberstein 2001, MulacJericevic et al. 2003). The cyclic changes in estrogen levels during estrous cycle result in
duct elongation, branching, thickening and eventually differentiation into lobules and
alveoli (Russo et al. 1999).
Full development and differentiation of the mammary gland only takes place during
pregnancy and lactation. Mammary gland growth reaches the fastest stage during the later
stage of pregnancy. Both estrogen and progesterone levels are elevated and these two
hormones synergize to stimulate the development of ducts and lobule alveoli during
pregnancy (Glasier et al. 1990). As pregnancy progresses, the entire fat pad is gradually
filled with ducts and alveoli (Tucker 1987). Mammary gland growth continues until the
peak of lactation. However, the milk secretory cells only develop during pregnancy, and
the number of secretory cells does not increase any more during lactation. Therefore the
udder contains more secretory cells at the beginning than at the end of lactation (Anderson
et al. 1990).
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Effect of Estrogen in Normal Mammary Gland Development
The development of mammary glands is regulated by systemic hormones and
locally produced growth factors. The most important systemic hormones involved in the
development of mammary glands include estrogen, progesterone, growth hormone,
prolactin, oxytocin glucocorticoids, thyroid hormones and insulin (Hadley et al.). In
addition to the systemic hormones, the mammary gland itself can also produce growth
factors which regulate mammary gland development including insulin-like growth factor I
(IGF-I), epidermal growth factors (EGF), hepatocyte growth factor (HGF), fibroblast
growth factor (FGF), keratinocyte growth factor (KGF), transforming growth factor 
(TGF-) and parathyroid hormone related protein (PTHrP).
Estrogens play a fundamental role in mammary gland development. Locally
administrated anti-estrogen is able to inhibit mammary cell proliferation and ductal growth
in the mammary gland, suggesting that estrogen is a positive regulator (Silberstein et al.
1994). The essential role of estrogen has been further proved by the classical hormone
ablation experiment using OVX animals whose ovaries have been removed (Berry et al.
2003). The OVX animals exhibit impaired and limited ductal growth in the mammary
gland. The total mammary gland size decreases to 1/3 of the size of control animals. The
proliferation rate of mammary epithelial cells in OVX animals is significantly lower than
that in wild type animals (Berry et al. 2003). Administration of estrogen along with other
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ovarian hormones is able to stimulate and even restore mammary gland growth in OVX
animals, indicating that estrogen is essential in mammary gland development (Cheng et al.
2005).
Estrogen can stimulate mammary gland development directly or through other
growth factors. Several factors have been demonstrated to mediate indirect effect of
estrogen. Estrogen upregulates prolactin gene transcription and promote the secretion of
prolactin (Scully et al. 1997). In addition, estrogen inhibits release of dopamine, a negative
regulator of prolactin synthesis and secretion, further elevating the level of prolactin (Ojeda
et al. 1974, Gudelsky et al. 1981).
Estrogens also induces the expression of progesterone receptors and increase the
proliferation of mammary epithelial cells synergistically with progesterone during
pregnancy when both hormones are present at high levels, leading to the significant
increase in mammary gland growth rate (Clarke et al. 1997).
In the mammary gland, insulin-like-growth factor I (IGF-I) and estrogen can act
synergistically to stimulate cell proliferation (Ruan et al. 1995). The expression of IGF-I is
regulated by the growth hormone and estrogen. IGF-I is able to activate MAPK and
PI3K/AKT pathway which phosphorylate and activate ERα (Kato et al. 1995). Upon
binding of estrogen, ERα rapidly induces the IGF-I receptor (IGF-IR) to activate the
signaling cascade, forming a rapid estrogen feedback stimulation loop (Kahlert et al. 2000).
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Estrogen stimulates production of EGF, transforming growth factor-α (TGF-α)
and amphiregulin in the mammary gland (Mallepell et al. 2006, Ciarloni et al. 2007). These
growth factors belong to the EGF protein family which plays an important role in
regulating cell proliferation and differentiation. Amphiregulin, a required for ductal
elongation and side branching in the mammary gland, is an important paracrine mediator
of estrogen function (Ciarloni et al. 2007).
EGF signaling pathway, which has been shown to be downstream of ERα
signaling, is required by the stimulatory effect of ER on mammary gland development.
Estrogen induces rapid phosphorylation of EGF receptors (EGFR) and many EGFR ligands
have been described as estrogen target genes (Filardo et al. 2000, Filardo et al. 2002,
Britton et al. 2006). Inhibition or selective knockdown of EGFR lead to diminished
estrogen-induced MAPK activation and block the stimulatory effect of estrogen on cell
growth (Santen et al. 2009).
The crosstalk between ER activity and TGF- signaling have been reported in a
number of studies. TGF- is a pluripotent cytokine that can arrest cell cycle by inhibiting
cyclin-dependent kinase activities and by reducing the expression level of c-myc and
inducing cell apoptosis (Donovan et al. 2000, Ewan et al. 2002, Heldin et al. 2009). In
contrast, ERα has a strong mitogenic activity which enhances the transcriptional activation
of cyclin D and c-myc and prevents apoptosis (Dubik et al. 1987, Musgrove et al. 1994,
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Lewis-Wambi et al. 2009). Studies suggested that dysregulation of TGF- may promote
the proliferation of ERα positive cells (Ewan et al. 2005). Estrogen treatment inhibits
transcriptional activity of TGF- through MAD-related protein 3 (Smad3) (Matsuda et al.
2001, Kleuser et al. 2008). Treatment of anti-estrogen promotes the secretion of TGF- as
well as the expression of TGF- receptor leading to inhibited cell proliferation (Chen et al.
1996).

Expression of Estrogen Receptors in the Mammary Gland
In the mammary gland, both ERα and ER are expressed, but with distinct
expression patterns. ERα is expressed in luminal epithelial cells but not in stromal or
myoepithelial cells (Saji et al. 2000). ER is expressed not only in luminal epithelial cells
but also in some stromal cells and myoepithelial cells (Palmieri et al. 2002). In the
mammary gland, the expression level of ERα is generally much higher than ER. However
the dominant type of estrogen receptor in stromal cells is ER (Jensen et al. 2001,
Pettersson et al. 2001, Shyamala et al. 2002).
The expression pattern and level of estrogen receptors undergo dynamic changes in
different stages of mammary gland development and during the estrous cycle.
Approximately 70% of epithelial cells express ER throughout all developmental phases
(Schams et al. 2003). In contrast, the percentage of ERα positive cells varies in different
development stages. In human mammary gland, ERα can be found in 20% of epithelial
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cells in the follicular phase of the estrous cycle (Clarke et al. 1997). In rodent, ERα protein
level changes while ERα mRNA level remains steady during the estrous cycle (Cheng et
al. 2005). The highest ERα expression is in the proestrus phase of the estrous cycle and the
expression level declines as estrogen levels increase (Cheng et al. 2005). The percentage
of ERα positive cells increases during puberty stage and gradually decreases during
pregnancy. It rises again during lactation, and drops to a basal level in post-lactation stage
(Lemmen et al. 1999, Saji et al. 2000). The percentage of ERα positive cells increases after
OVX, presumably due to decreased level of circulatory estrogens (Berry et al. 2003, Song
et al. 2012). Approximately 60% of epithelial cells coexpress ERα and ER during
lactation, but cells coexpressing ERα and ER are rarely detected during pregnancy (Saji
et al. 2000).

Function of ERα in Mammary Gland Development
ERα is the first discovered estrogen receptor and for many years it was the only
known ER. Its expression level is much higher than that of ERβ, known as the primary
estrogen receptor expressed in the mammary gland. The function of ERα in mammary
gland development has been elucidated using the ERα knockout mice (Bocchinfuso et al.
1997). The mammary gland is the same before puberty in the ERα knockout mouse and
wild type mouse. At the beginning of female puberty, terminal end buds start to form and
ducts start to elongate in the mammary gland of wild type mouse. However, there is no
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terminal end buds detected in the ERα knockout mouse (Mallepell et al. 2006). Only
prepubertal rudimentary ductal structures can be found in the mammary gland of the ERα
knock-out mouse, indicating that ERα is essential for postnatal mammary gland growth but
not required for embryonic mammary growth (Bocchinfuso et al. 1997). In order to
investigate whether the developmental defect is intrinsic to mammary epithelium or the
mammary stroma, the tissue recombination experiments were carried out. ERα -/mammary epithelial cells from ERα -/- mice failed to develop normal structure when
transplanted into the wild type clear fat pad, while the wild type mammary epithelium is
able to develop normally in the clear pad of ERα knockout recipient (Mallepell et al. 2006).
These results suggest that the primary target of estrogen is the epithelial cells and the direct
response of the mammary stroma to estrogen is not required for mammary gland
development.
ERα regulate transcription of many genes involved in promoting cell proliferation
and inhibiting cell apoptosis. Cyclin D, a major regulator controlling entry into the
proliferative stage of the cell cycle, is one of the target genes regulated by ERα (Liu et al.
2002). Impaired mammary gland was found in cyclin D1 knockout mice, indicating that
the mammary epithelial cells is unable to respond appropriately to morphogenetic hormone
signals (Sicinski et al. 1997). High levels of cyclin D can be found in breast cancer tumors
and are positively associated with ERα (Simpson et al. 1997). ERα is able to increase
transcription of cyclin D hence leading to up-regulation of cyclin D protein (Prall et al.
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1997, Steeg et al. 1998). Estrogens induce cyclin D expression through a ERE-independent
pathway since the cyclin D promoter region does not contain a ERE sequence (Herber et
al. 1994). Instead, the estrogen-ERα complex binds to sequences containing the AP1 site
or cAMP response element (CRE) to promote cyclin D transcription (Liu et al. 2002).
c-Myc is another estrogen-target gene involved in regulation of mammary cell
growth. The regulatory region of c-myc gene contains ERE, where the estrogen-ERα
complex binds to regulate c-myc transcription (Dubik et al. 1992). Similar to ERα,
overexpression of c-myc can be found in 70% of breast cancer tumor samples (Deming et
al. 2000). In 15.5% of breast cancer tumor samples, c-myc expression level is three times
higher than that in normal breast tissue (Bièche et al. 1999). Estrogen significantly
increases c-myc protein levels which result in enhanced cell cycle progression (Mawson et
al. 2005).
The proto-oncogene, c-fos, is widely expressed in the mammary gland. c-Fos is
both a direct and indirect transcriptional regulator of cyclin genes and functions as a critical
link between estrogen stimulation and cell cycle progression (Brown et al. 1998). Estrogens
induce c-fos expression and c-fos transactivation by estrogens modulates expression of
multiple genes through interactions with AP1 site in corresponding promoters to promote
cell proliferation (Cohen et al. 1989).
Breast cancer type 1 susceptibility protein (BRCA1) is responsible for DNA
repairing and serves as a tumor suppressor (DengÃ et al. 2000). BRCA1 mutations can be
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found in approximately 5% of all breast cancer cases and 45% of familial breast cancer
cases (Yoshida et al. 2004). BRCA1 inhibits ERα activity in two ways. One way is that
BRCA1 binds to the AF2 domain of ERα to inhibit ERα’s transcriptional activity (Fan et
al. 1999). The other way is that BRCA1 downregulates ERα coactivator p300 gene
expression which also leads to reduced ERα activity (Fan et al. 2002).
Besides cell proliferation, apoptosis is another important aspect during mammary
gland development. In mammary gland due to the drop in estrogen levels, apoptosis reaches
the peak at the end of luteal phase (Ferguson et al. 1981). Estrogen is able to regulate a
large set of genes that are related to apoptosis. Apoptosis regulator Bcl-2 family contains
proapoptosis and antiapoptosis members. The Bax, BAD, Bak and Bok are proteins that
promote cell death, whereas Bcl-2, Bcl-xL and Bcl-w inhibit cell death (Yang et al. 1995).
Bcl-2 is induced by estrogen through the classical ERα signaling pathway (Martin et al.
2013). Consistent with ERα expression, expression of Bcl-2 reaches the peak at the end of
follicular phase and gradually decreases during the luteal phase (Sabourin et al. 1994). The
lower ratio of Bcl-2/Bax is able to increase caspase-3 expression and promotes apoptosis
(Martin et al. 2013). Estrogen treatment significantly increases Bcl-2 level but only slightly
increases Bax level, consistent with the negative effect of estrogen on apoptosis (Helguero
et al. 2005).
Although ERα is essential for mammary gland development, the detailed
mechanism is still not fully understood. In normal mammary gland, ERα cannot be detected
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in proliferating mammary epithelial cells indicating that estrogen stimulates growth
indirectly (Clarke et al. 1997, Russo et al. 1999, Cheng et al. 2005). The paracrine model
is the most accepted model explaining such observation. In this model, ERα positive cells
do not proliferate but produce and secret growth factors when they are stimulated by
estrogen. These growth factors stimulate the neighboring ERα negative cells to proliferate
(Clarke et al. 1997, Mallepell et al. 2006).
The EGF family member, amphiregulin, is the most important growth factor
secreted by ERα positive cells and mediates estrogen action (Ciarloni et al. 2007). Local
administration of EGF or amphiregulin in OVX mice induces mammary cell proliferation
and ductal growth, indicating that EGF or amphiregulin acts downstream of estrogen
signaling (Snedeker et al. 1991, Kenney et al. 1996). The morphology of mammary gland
in amphiregulin knockout mice is the same as that in OVX mice suggesting that
amphiregulin is required in epithelial cell proliferation, terminal end buds formation and
ductal elongation (Ciarloni et al. 2007). Consistent with the paracrine model, estrogen
induces amphiregulin protein secretion and inhibits the expression of EGFR in ERα
positive cells. In ERα negative cells, secreted amphiregulin activates EGFR signaling and
stimulates cell proliferation (Kariagina et al. 2010).
However, in some breast cancer tumor cells, ERα has been observed to co-localize
with cell proliferation markers. The percentage of this type of cells varies from 0% to 5%
of total cells among different patients (Shoker et al. 1999). Therefore some researchers
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proposed that ERα stimulates cell proliferation through both autocrine and paracrine
models. It has been shown that the half-life of ERα is very short, only one or two hours.
Once ERα is activated by estrogen, it is quickly degraded subsequently (Cheng et al. 2004).
This characteristic of ERα may account for the special separation of ERα staining and cell
proliferation marker in normal breast tissue at detection. In the breast cancer cells however,
ERα is not degraded as quickly and can be detected in all phases of cell cycle (Tan et al.
2009). Therefore these researchers believe that a switch from a paracrine to an autocrine
mechanism might be an important part of the tumorigenic process (Cheng et al. 2004, Tan
et al. 2009).

Function of ERβ in Mammary Gland Development
Compared with ERα, the other estrogen receptor, ERβ, is much less studied and its
function remains elusive. In the ER knockout mice, the histology of ovary and uterus is
only mildly affected and the overall structure of mammary gland during puberty is
relatively normal (Krege et al. 1998). The side branching is delayed in the ER knockout
mice, which may be due to the loss of ER or decreased progesterone secretion (Antal et
al. 2008). During pregnancy, mammary glands of the ER knockout mice have normal
structures and can lactate normally as wild-type mammary glands do (Förster et al. 2002).
However, mammary glands in the ER knockout mice have less developed lobuloalveolar
structures, suggesting that ERβ is involved in alveologenesis and differentiation (Förster et
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al. 2002, Walker et al. 2004). Observations from ER knockout mice indicate that ER is
not essential for mammary gland development and ERα is the major type of estrogen
receptor which is able to mediate the action of estrogen on its own.
However, ER expression has been detected in mammary epithelial cells and
stromal cells and many studies have reported that ER negatively regulates proliferation
of both normal and breast tumor cells (Lazennec et al. 2001, Liu et al. 2002, Visvader et
al. 2003, Paruthiyil et al. 2004, Helguero et al. 2005, Song et al. 2012). The expression of
ERβ in MCF7 and T47D xenografts has been shown to inhibit tumor growth (Paruthiyil et
al. 2004, Hartman et al. 2009). Moreover, ER expression is found decreased or lost in
many primary breast tumors and the ER level is significantly associated with the survival
rate (Zhao et al. 2003, Girault et al. 2004, Gruvberger-Saal et al. 2007, Honma et al. 2008).
It has been shown that ERβ may inhibit cell proliferation at multiple levels,
although detailed molecular mechanism of the ERβ inhibitory effects is still under
investigation. ER inhibits the expression of positive cell cycle progression molecules
including c-myc, cyclin A, cyclin D and cyclin E, and promotes the expression of negative
ones including p21 and p27, leading to a G1/2 cell cycle arrest. (Paruthiyil et al. 2004,
Strom et al. 2004). ER inhibits TGFα expression, suggesting that ERβ may affect the
production and/or secretion of growth factor to regulate cell proliferation (Lazennec et al.
2001, Hartman et al. 2009). ERβ may also regulate cell proliferation through interacting
with ERα. ERα homodimers increase target gene transcription while the heterodimers of
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ERα/ER do not have such effect, indicating a negative role of ER on ERα actions. ERα
induced cyclin D and amphiregulin expression is suppressed by ER (Song et al. 2012).
ERK1/2 activated by ERα is also repressed ER (Cotrim et al. 2012).
Although the inhibitory effect of ERβ has been demonstrated by many studies, in
one in vivo study using OVX mice, activation of ERβ was shown to stimulate cell
proliferation (Cheng et al. 2004). Another in vitro study suggests that ERβ has stimulatory
effect on cell growth in an ER negative cell line (Hou et al. 2004). Therefore the role of
ERβ in cell proliferation are still controversial from studies using different experimental
models.
ER has been shown to play a role in mammary cell apoptosis as well. Many studies
suggested that ER is able to increase mammary cell death in normal breast cells and breast
cancer cells (Helguero et al. 2005, Hodges-Gallagher et al. 2008). Activation of ERα
significantly decreases expression of Bcl-x, a positive regulator of apoptosis, in contrast to
the fact that activation of ERβ keeps Bcl-x level high (Helguero et al. 2005).
Function of Estrogen in Breast Cancer
Estrogens are essential for various normal physiological processes in the body.
However, evidence has shown that estrogens are positively related to breast cancer and
extended exposure to estrogen in females is associated with increased risk of breast cancer
(Butler et al. 1979). The risk of breast cancer is significantly higher in women with higher
estrogen levels in blood plasma (Butler et al. 1979). Bilateral oophorectomy before age 35
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reduces the risk of breast cancer by 40-75% (Feinleib 1968, McPerson et al. 2000). Women
with early menarche (before age 12) and/or late menopause (after age 55) that have more
menstrual cycles also have a higher risk of breast cancer (Ritte et al. 2012). Late age of
first pregnancy and nulliparity increase the risk of breast cancer while the first pregnancy
before age 20 reduces breast cancer risk by 50% (Clemons et al. 2001, Bernstein 2002, Yue
et al. 2012). Early pregnancy and high estrogen levels during pregnancy may reduce the
risk of breast cancer by altering the sensitivity of mammary epithelial cells to stimulatory
effect of estrogen on cell proliferation after pregnancy. In addition, fully development of
breasts reduces the number of stem or progenitor cells leading to reduced risk of
tumorigenesis (Britt et al. 2007, Siwko et al. 2008). HRT has been reported to increase the
risk of breast cancer, especially for women who have received estrogen and progestin
regimen (Fernandez et al. 2003, Heiss et al. 2008, Hernán et al. 2008). It is still debating
whether the oral contraceptives would increase the risk of breast cancer (Kumle et al. 2002,
Hunter et al. 2010, Marchbanks et al. 2012, Nelson et al. 2012).
Block of estrogen synthesis with inhibitors of aromatase, the key enzyme in
estrogen biosynthesis, has been used to prevent and treat breast cancer in postmenopausal
women with ER positive tumor cells. Although the estrogen concentration is very low in
these patients, aromatase in their breast tissue is still able to synthesize estrogen which
stimulates breast cell proliferation. The development of aromatase inhibitor began in the
1970s (Thompson Jr et al. 1979, Marsh et al. 1985, Brueggemeier et al. 1990). Nowadays
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the third generation of aromatase inhibitor (exemestane) significantly reduces the risk of
invasive breast cancers by 65% in postmenopausal women (Goss et al. 2011). The
aromatase inhibitors can be used alone or combined with tamoxifen for early breast cancer
therapy, and anastrozole and letrozole have been proved to be more effective than
tamoxifen as the first line therapy in postmenopausal women with advanced breast cancer
(Bonneterre et al. 2000, Nabholtz et al. 2000, Bonneterre et al. 2001).

ERα and Breast Cancer
In normal breast tissue, only approximately 10% of cells are ERα positive (Khan et
al. 1998). This percentage increases in proliferative benign disease that is often related to
ductal carcinoma in situ (DCIS) (Shoker et al. 1999). Overexpression of ERα leads to overproliferation and tumorigenesis in mammary gland (Frech et al. 2005). About 70% breast
cancer tumors are considered as ERα positive tumors containing 40% to 70% ERα positive
cells (Regan et al. 2006). Nowadays, as a diagnostic marker, ERα expression status is
regularly measured in breast cancer patients. Deregulation of ERα may change the cell
cycle progression and directly induce ERα positive cancer cells to proliferate. The crosstalk
between ERα and other signaling pathways plays an important role in invasion and
metastasis of breast cancer cells. ERα positive tumors are often metastatic to bone and lung
(Alanko et al. 1985, Maki et al. 2000, Kennecke et al. 2010). ERα regulates the
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deacetylation of tubulins, which promotes breast cancer cell migration, is the first key step
in metastatic process (Alberts et al. 2002, Azuma et al. 2009).

ERβ and Breast Cancer
In contrast to the positive correlation of ERα expression level and breast cancer,
ER expression level decreases in breast tumors (Zhao et al. 2003, Girault et al. 2004,
Gruvberger-Saal et al. 2007, Honma et al. 2008). Hypermethylation of DNA in the
promoter region of ER may partial account for the down-regulation of ERβ in breast
cancer cells (Zhao et al. 2003, Rody et al. 2005). High levels of ER expression in breast
tumor were found to associate with a better response to tamoxifen and a longer survival
time (Honma et al. 2008). This observation may be due to the inhibition of cell proliferation
by ER. It has been shown that ER expression level is inversely correlated with cell
proliferation marker Ki67 (Roger et al. 2001). In addition, clinical studies also found that
expression of ER in ERα positive breast tumors reduces cell motility and invasion
(Järvinen et al. 2000).
The function of ER as a tumor suppressor in mammary epithelial cells has been
studied in a number of studies. Paruthiyil and his colleagues found that ERβ inhibits breast
cancer cell proliferation by inhibiting cyclin A, cyclin D and c-myc gene transcription and
increasing the expression of cell cycle inhibitors, p21 and p27. Overexpression of ERβ
prevents tumor formation in the mouse xenograft model (Paruthiyil et al. 2004). Moreover,
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ER is able to counteract the effects of ERα in mammary gland. The expression level of
p21 is much higher in ERα and ER co-expressing cells than that in ERα only cells (Chang
et al. 2006). Relative expression levels of ERα and ER in mammary gland modulate the
cell proliferation rate and apoptosis (Ström et al. 2004, Chang et al. 2006). Furthermore,
ER inhibits breast cancer cell migration and invasion in a ligand independent manner
(Lazennec et al. 2001). Platet and his colleagues found that cell invasion was decreased 2
fold by the expression of ER (Platet et al. 2000). ER also inhibits angiogenesis by
downregulating the expression and secretion of vascular endothelial growth factor (VEGF)
and platelet-derived growth factor  (PDGF) (Hartman et al. 2006).

Selective ER Modulators and Breast Cancer
Selective estrogen receptor modulators (SERMs) are a class of compounds that bind
to ERα and ER and exert estrogenic or anti-estrogenic activities in different tissues. Some
SERMs are used to treat breast cancer, including tamoxifen, raloxifene, toremifene and
lasofoxifene.
Tamoxifen has been widely used in the clinic to treat early and advanced ERα
positive breast cancer for over 35 years. Tamoxifen is also used to prevent breast cancer in
women who are at high risk of developing the disease. In addition it is the most common
drug to treat male breast cancer (Gethins 2012). Similar to estrogen, tamoxifen binds to
ERα and induces dimerization. However, unlike estrogen, tamoxifen inhibits activation of
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the AF2 domain on ERα and blocks transcription of ERα target genes. The effect of
tamoxifen in different tissues depends on the existence of different coactivators and
corepressors in different cells (Jordan et al. 2007). For instance, tamoxifen performs
agonistic activity in endometrial cells where the coactivator SRC level is relative high.
However, tamoxifen exhibits antagonistic activity in mammary cells where the SRC level
is lower (Shang et al. 2002). Thus, tamoxifen used to treat breast cancer increases the risk
of endometrial cancer (Bergman et al. 2000, Swerdlow et al. 2005).
Like tamoxifen, another SERM, raloxifene, has a mixed pharmacological effects
on breast cancer. It acts as estrogen agonist or antagonist in different tissues (Brzozowski
et al. 1997, Wijayaratne et al. 1999). In the bone, raloxifene acts as estrogen agonist to
prevent and treat osteoporosis, whereas in the mammary gland and uterus raloxifene acts
as estrogen antagonist to inhibit cell proliferation (Haskell 2003). Therefore, compared
with tamoxifen, raloxifene treatment has a 50% reduction in the risk of endometrial cancer
(DeMichele et al. 2008).
The SERM, toremifene, is used to treat metastatic breast cancer in postmenopausal
women with ERα positive tumors or tumors with unknown ER status. Toremifene has
structure and properties similar to tamoxifen (Hayes et al. 1995). Hence the tamoxifen
treatment and toremifene treatment have similar efficacy and adverse effects (Marttunen et
al. 1998).
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Lasofoxifene is mainly used to prevent and treat osteoporosis and vaginal atrophy.
In the postmenopausal women, 0.5mg of lasofoxifene per day significantly reduces the risk
of total breast cancer by 79% and ERα positive breast cancer by 83%. Lasofoxifene
treatment increases endometrial thickness, but does not increase the risk of endometrial
cancer (LaCroix et al. 2010).

Medical Application

Contraceptive Application
Estrogens, especially 17-estradiol, are essential for female fertility. The
estrogen-based contraceptive methods include oral pills, transdermal patches, vaginal rings
and injectable contraceptives. Currently combined oral contraceptive pills (COCP) are the
most popular method of birth control with more than 100 million women worldwide and
about 12 million women in the United States using COCP as her birth control method
(Mosher et al. 2004). In last 50 years after the first COCP approved in 1960, COCP went
through a remarkable evolution which reflected our increased knowledge about hormonal
safety issues. The doses of the hormones in the pills have dramatically decreased and new
hormone compounds have been introduced (Hatcher 2007, Speroff et al. 2010).
The estrogen and progestin combination in COCP reduces circulating levels of
gonadotropins (FSH and LH) and prevents ovulation through an effect on both pituitary
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and hypothalamus, hence providing safe, effective and reversible contraceptive
(Vandenberg et al. 1974, Meyers et al. 2001, Beral 2003).
Estrogen in the pill also serves two other purposes. First, it stabilizes the
endometrium so that irregular shedding and incidence of breakthrough bleeding can be
minimized. Second, estrogen is required to potentiate the action of progesterone
components by stimulating the expression of progesterone receptors (Kraus et al. 1993, Ing
et al. 1997).
Besides being a contraceptive, COCP also solves many menstrual related
problems. The menstrual cycle related health benefits include decreased dysmenorrhea
(painful periods), decreased menstrual blood loss, reduction in premenstrual syndrome
(PMS) symptoms, reduction of premenstrual dysphoric disorder (PMDD), reduced risk of
postovulatory ovarian cysts and improvement in menstrual migraines (Hatcher 2007). In
addition, COCP has been used to treat other medical conditions, such as polycystic ovary
syndrome (PCOS), endometriosis, amenorrhea and adenomyosis (Hatcher 2007).
Sometimes COCP is used to treat acne or hirsutism. Three different oral contraceptives
have been FDA approved to treat moderate acne if the patient is at least 14 or 15 years old,
has already begun menstruating, and needs contraception (Food 2011).
However, hormone-based contraceptives have side effects. There is evidence
supporting that the COCP increases the risk of venous thromboembolism (Jick et al. 2000).
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Contradictory research results exist in studies on the effect of hormone-based
contraceptives on the risk of breast cancer, liver cancer and cervical cancer (Hatcher 2007).

Hormone Replacement Therapy
Menopause is a natural event which normally occurs in women in their late 40s
or early 50s. Due to the decrease in estrogen production, a number of physiological
changes take place such as hot flushes, night sweating, mood and sleep disturbances,
fatigue, difficulties with memory and urogenital dysfunction. About 80% women have
one or multiple symptoms that may last for several years (Hickey et al. 2012). HRT is an
effective therapy to ameliorate these symptoms suggested by the Women's Health
Initiative study, Heart and Estrogen/progestin Replacement study (Hulley et al. 1998,
Keating et al. 1999, Genazzani 2001, Rossouw et al. 2002). There are two main types of
HRT: estrogen hormone therapy and progesterone/progestin-estrogen hormone therapy.
Estrogen can be given oral, transdermal or intravaginal daily. Progesterone can be given
oral, transdermal or delivered via an intra-uterine device daily or sequentially.
Besides the effective control of menopausal symptoms, HRT has several side
effects. About 14% women who receive transdermal HRT have local skin irritation (Ibarra
de Palacios et al. 2002). Other adverse effects of HRT include irregular bleeding, vaginal
discharge, flushing, headache, nausea, vomiting and depression. WHI data have suggested
that HRT may significantly increase the incidence of stroke (Rossouw et al. 2002). Current
51

users of estrogen regimen have an increased risk of breast cancer and uterus cancer, and
this risk increases with duration of use (Hofseth et al. 1999, Rossouw et al. 2002). The
adverse effect of estrogen on uterine endometrium can be opposed by progestins. However,
estrogen-plus-progestin HRT regimen impose substantially higher risk of breast cancer
than estrogen alone regimen (Grady et al. 1995, Persson et al. 1999, Ross et al. 2000).
Due to the adverse effects of HRT, new regimens need to be developed. The key
method to improve HRT is the development of estrogen mimics that can act as estrogen
in some tissues, but not in others. SERMs are such compounds that mimic estrogen in a
tissue-specific manner. Tamoxifen which is widely used for the treatment of breast cancer
can act as estrogen in uterus, bone and cardiovascular system, but not in breast (Love et
al. 1992, Grey et al. 1995, Macgregor et al. 1998). Another SERM, raloxifene has the
beneficial effect of estrogen in bone and cardiovascular system while it does not have
estrogenic effects in uterus and breast (Delmas et al. 1997, Barrett-Connor et al. 1998,
Goldstein 1998).
Summary
Estrogen is an essential steroid hormone regulating growth and differentiation in
various systems and tissues. The biological functions of estrogen are mediated by two types
of estrogen receptors, ERα and ERβ, which may have different functions in different tissues.
This thesis examines the role of ERα and ERβ in mammary gland and other tissues and
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explores the potential use of ERβ in breast cancer treatment and hormone replacement
therapy.
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CHAPTER 2: Estrogen receptor-beta agonist
diarylpropionitrile counteracts the estrogenic activity of
estrogen receptor-alpha agonist propylpyrazole-triol in the
mammary gland of ovariectomized Sprague Dawley rats
Abstract
Although estrogen can bind both types of estrogen receptors, estrogen receptoralpha (ERα) is dominant in mediating estrogenic activity in the mammary gland and uterus.
Excessive estrogenic activity such as estrogen-based postmenopausal hormone
replacement therapy increases the risk for breast and endometrial cancers. The adverse
effect of estrogen on uterine endometrium can be opposed by progestins; however,
estrogen-plus-progestin regimen imposes substantially greater risk for breast cancer than
estrogen alone. In this study, we used ERα selective agonist propylpyrazole-triol (PPT) and
ERβ- selective agonist diarylpropionitrile (DPN) to activate ERα and estrogen receptorbeta (ERβ) separately in an ovariectomized rat model and determined whether PPTactivated ERα function in the mammary gland can be suppressed by DPN activated ERβ.
Ovariectomized rats were randomly divided into six groups and treated with DMSO
(control), DPN, PPT, PPT/DPN, PPT/Progesterone, and PPT/Progesterone/DPN,
respectively. In the mammary gland, PPT but not DPN increased cell proliferation and
amphiregulin gene expression; importantly, the stimulatory effect of PPT on mammary cell
proliferation and amphiregulin gene expression can be suppressed by DPN. In the uterus,
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the effect of PPT on uterine weight and endometrial cell proliferation was not inhibited by
DPN but can be inhibited by progesterone. These data provide in vivo evidence that PPT
activated ERα activity in the mammary gland can be opposed by ERβ-selective agonist
DPN, which may be explored for the development of better hormone replacement therapy
regimen with less risk for breast cancer.

Keywords:
Estrogen receptor
Diarylpropionitrile
Propylpyrazole triol
Mammary gland
Breast cancer
Hormone replacement therapy
Introduction
Estrogen has profound effects on a broad range of tissues and organs involved in
many physiological processes. Drop in estrogen production after menopause is responsible
for many postmenopausal symptoms, thus estrogen or estrogen-plus progestin can be used
for hormone replacement therapy (HRT) to ameliorate postmenopausal symptoms. A
major adverse effect associated with estrogen-based HRT is the increased risk for breast
cancer and uterine endometrial hyperplasia and malignancy (Rossouw et al. 2002, Banks
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et al. 2003). The adverse effect of estrogen on uterine endometrium can be opposed by
progestins; however, estrogen-plus-progestin HR regimen imposes substantially greater
risk for breast cancer than estrogen alone (Persson et al. 1999, Pike et al. 2000, Ross et al.
2000, Schairer et al. 2000, Banks et al. 2003). While the two types of estrogen receptors,
ERα and ERβ, bind to natural estrogen with similar affinity, ERα is the dominant receptor
that mediates the estrogenic responses in most estrogen regulated tissues including the
mammary gland

and uterus (Kuiper et al. 1997, Couse et al. 1999, Dupont et al. 2000,

Deroo et al. 2006, Mallepell et al. 2006, Harris 2007). Deregulation of ERα expression and
activity accounts for the majority of breast and endometrial cancers. Approximately 70%
of breast tumors and 60% of endometrial tumors are ERα-positive tumors (Ferrandina et
al. 2005, Regan et al. 2006). In many breast tumors, the percentage of ERα-positive cells
is much higher than that in the normal mammary gland (Clarke et al. 1997, Russo et al.
1999, Shoker et al. 1999, Regan et al. 2006). Furthermore, ERα may mediate cell
proliferation differently in breast tumors. In the normal mammary gland, ERα+/Ki67+ cells
are very rare and it is believed that ERα acts in a paracrine manner to promote neighboring
ERα-negative cell to proliferate (Shoker et al. 1999, Schairer et al. 2000, Banks et al. 2003,
Cheng et al. 2005, Mallepell et al. 2006). In ERα-positive breast tumors or cancer cell lines,
the percentage of ERα+/Ki67+ cells are much higher than that in the normal mammary
gland and that ERα may directly stimulate ERα-positive cancer cells to proliferate (Clarke
et al. 1997, Ross et al. 2000, Tan et al. 2009). Deregulated expression of ERα in transgenic
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mice leads to mammary tumorigenesis and makes the uterus more susceptible to estrogen
induced uterine tumorigenesis (Couse et al. 1997, Tilli et al. 2003, Frech et al. 2005).
Unlike ERα, ERβ is not required for mammary gland and uterus development (Krege et al.
1998, Dupont et al. 2000, Förster et al. 2002, Mallepell et al. 2006). Epidemiological
studies indicate that ERβ expression is lost or decreased in many breast and endometrial
tumors, indicating that ERβ may function as a tumor suppressor (Roger et al. 2001,
Shaaban et al. 2003, Girault et al. 2004).
The precise mechanism(s) by which estrogen promotes tumorigenesis in the
mammary gland and uterine endometrium is not fully understood. A major effect of
estrogen on the mammary gland and uterus is to stimulate cell proliferation (Berry et al.
2003, Visvader et al. 2003, Cheng et al. 2004, Slayden et al. 2004). It has been found that
estrogen-based HRT significantly increases breast epithelial cell proliferation in
postmenopausal women (Hofseth et al. 1999). Deregulation of cell proliferation by
oncogenes and tumor suppressors is one of the hallmarks of cancer cells (Hanahan et al.
2000, Meyers 2005). Consistent with its role in breast and endometrial malignancy, ERα
is essential and sufficient to mediate estrogen induced cell proliferation (Shoker et al. 1999,
Dupont et al. 2000, Harris et al. 2002, Berry et al. 2003, Slayden et al. 2004). In contrast
to the positive role of ERα in cell proliferation, ERβ may function as a negative regulator
of cell proliferation. Loss of ERα could lead to increased cell proliferation, whereas
overexpression of ERβ has been found to inhibit cell proliferation and xenograft tumor
91

formation in several breast and endometrial cell lines (Dupont et al. 2000, Nilsson et al.
2001, Berry et al. 2003, Paruthiyil et al. 2004, Ström et al. 2004, Cheng et al. 2005,
Helguero et al. 2005, Hartman et al. 2006, Chen et al. 2007, Covaleda et al. 2008, Treeck
et al. 2008). The molecular mechanism of ERβ action is not fully understood (Harris 2007,
Deroo et al. 2010, Warner et al. 2010). Studies using in vitro cell lines have demonstrated
that ERβ can antagonize ERα in gene expression, cell cycle progression, and cell
proliferation (Clarke et al. 1997, Couse et al. 1997, Paech et al. 1997, Hall et al. 1999,
Harris et al. 2002, Liu et al. 2002, Paruthiyil et al. 2004). ERα and ERβ may form a subtle
balance to regulate estrogen signaling in mammary and endometrial cell proliferation, loss
of the balance may lead to tumor initiation and progression (Matthews et al. 2003).
In addition to genetic modification of estrogen receptor expression, ER-selective
agonists have been developed to determine the biological functions of ERα and ERα (Ström
et al. 2004, Harris 2006, Harris 2007, Paruthiyil et al. 2009, Minutolo et al. 2011). These
ER-selective agonists may also be used for pharmacological interventions of estrogenic
activity (Girault et al. 2004, Harris 2006, Harris 2007). Despite the significance of
estrogenic activity in mammary cell proliferation and tumorigenesis and that ERβ may
function as a tumor suppressor, in vivo studies of the ERβ-selective agonists in the
mammary gland are very limited (Harris et al. 2003, Slayden et al. 2004, Crabtree et al.
2006). It remains unknown whether endogenous ERβ can be activated to function as a
tumor suppressor in the mammary gland in vivo. In this study, we used ER-selective
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agonists propylpyrazole triol (PPT) and diarylpropionitrile (DPN) to separately activate
ERα and ERβ in an ovariectomized (OVX) rat model and determined whether ERαmediated estrogenic activity in the mammary gland can be inhibited by DPN activated ERβ.
In receptor competition binding assay for binding affinity relative to estradiol, PPT is an
ERα-selective agonist that has a 410 fold higher relative binding affinity to ERα than to
ERβ; DPN has a 70 fold higher relative binding affinity to ERβ than to ERα (Stauffer et al.
2000, Meyers et al. 2001). We demonstrated that ERα-mediated estrogenic activity in the
mammary gland can be opposed by the ERβ-selective agonist DPN in vivo, suggesting that
ERβ-selective agonists such as DPN may be explored for the development of better HRT
regimens to reduce or eradiate the risk for breast cancer.

Methods

Animals
All animal experimental procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of Vermont. Ovariectomized (OVX)
virgin female Sprague Dawley rats (Charles River - Canada) were housed with a 12-h light
and dark cycle and ad libitum access to food and water. Rats were ovariectomized at 5–6
weeks old and rested for two weeks before treatment. Five to six rats were randomly
assigned to each group and totally there are six groups, the control group, the DPN group,
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the PPT group, the PPT/DPN group, the PPT-plus-progesterone (PPT/P4) group, and the
PPT/P4/DPN group. PPT, DPN, and progesterone were obtained from Tocris Bioscience
and were dissolved in DMSO for stock solution. The drugs were administered by i.p.
injection once a day for three consecutive days; the control group rats received the vehicle
DMSO only. The dosage of the different drugs used in this study was as follows: PPT at
500 µg/kg BW (body weight), DPN at 1000 µg/kg BW, P4 at 20 mg/kg BW. BrdU (5bromo-2'-deoxyuridine, from Sigma) solution in PBS was injected (i.p., 20 mg/rat/d) at the
same time when the drug(s) was administered. Rats were sacrificed 16 h after the last
injection for biopsy sample collection. The timing of treatment and biopsy after the last
treatment was chosen based on other studies. In the literature, various lengths of treatment
ranging from a couple of hours to several weeks were used for the evaluation of different
endpoint parameters (Persson et al. 1999, Hanahan et al. 2000, Harris et al. 2003, Cheng et
al. 2004, Crabtree et al. 2006). The primary endpoint of evaluation in this study was cell
proliferation rate, the three day treatment period was chosen as it has been shown in several
studies that two to three day treatment significantly increased mammary cell proliferation
rate (Hofseth et al. 1999, Persson et al. 1999). Another reason that we did not choose shorter
than three days is the concern that the percentage of proliferating cells in OVX rats induced
by shorter treatment period would be too low to allow the detection of any inhibitory effect.
The drugs were administered in the afternoon for all three treatments; for the last treatment,
drug injections for different animals (with ear tag numbers) were administered at 15 min
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intervals so that each individual animal was killed at 16 h post the last treatment for biopsy
sample collection. Time course studies have shown that estrogen treatment for as short as
4 h significantly increased the percentage of cyclin D-staining cells in the mammary gland;
in our previous studies using ERα-positive MCF-7 cell line treated with estrogen,

we

noticed that the percentage of cells with the Ki-67 proliferation marker started to increase
around 12 h (Hofseth et al. 1999, Pike et al. 2000). Based on these time course studies, we
expected that the effect from the last treatment can be detected 16 h later. For mammary
gland biopsy, the fourth pair of mammary glands was harvested from each rat and weighed.
The right-side was fixed in neutral formalin for 48 h before being processed for paraffin
embedding. The left-side was snap-frozen and stored in liquid nitrogen for RNA isolation.
The uterus from each rat was first measured for uterine wet weight (UWW) and then fixed
in neutral formalin for 24–48 h before being processed for paraffin embedding.
The dosage selection for this study was based on the dosages used by other studies,
the relative binding affinity, and the relative transcriptional activity via ERE (estrogen
response element) (Kuiper et al. 1997, Kuiper et al. 1998, Persson et al. 1999, Ross et al.
2000, Stauffer et al. 2000, Meyers et al. 2001, Berry et al. 2003, Frasor et al. 2003, SánchezCriado et al. 2004, Crabtree et al. 2006, Covaleda et al. 2008, Engdahl et al. 2010). PPT
from 50 µg/d/rat to 1000 µg/d/rat was shown with very good response in the uterine
endometrium (Harris et al. 2002). The body weight of the rats in this study was
approximately 200 g, therefore the dose per rat was about 100 µg/d/rat for PPT, 200
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µg/d/rat for DPN, and 4 mg/d/rat for progesterone. In the transcriptional activity assay
using the U2OS cell system, it was shown that the maximal activity stimulated by PPT was
comparable to that by estradiol, and that the EC50 for estradiol via ERα was 8 pM and the
EC50 for PPT via ERα was 140 pM (Covaleda et al. 2008). The ratio of 8 pM estradiol/140
pM PPT can be converted as 20 µg/kg BW estradiol/500 µg/kg BW PPT, a dosage that
were expected to be functional in the mammary gland as well (Visvader et al. 2003,
Ferrandina et al. 2005, Meyers 2005, Li et al. 2006). The binding affinity of PPT to ERα is
approximately 49% of that of estradiol to ERα, or the conversion of 500 µg/kg BW PPT to
176 µg/kg BW estradiol (Stauffer et al. 2000). DPN at 1000 µg/kg BW was within the
range used by other studies for its effect on uterus, hot flush, osteoporosis, and
cardioprotection (Frasor et al. 2003, Sánchez-Criado et al. 2004, Bowe et al. 2006, Nikolic
et al. 2007, Bliedtner et al. 2010, Engdahl et al. 2010). The binding affinity of DPN to ER
is approximately 18% of that of estradiol to ER, or the conversion of 1000 µg/kg BW
DPN to 205 µg/kg BW estradiol (Meyers et al. 2001). Based on these calculations, the
theoretically converted PPT and DPN (to estradiol) would have DPN binding to ER and
PPT binding to ERα at a comparable level. Considering that estradiol may have a two to
ten-fold higher binding affinity for ERα than for ER, the ratio of DPN-ER/PPT-ERα
could be lower than the 1:1 ratio (Liu et al. 2002, Harris 2007, Warner et al. 2010). The
binding affinity of PPT to ER is 0.12% of that of estradiol to ER, or the conversion of
500 µg/kg BW PPT to 0.42 µg/kg BW estradiol, a concentration that would not interfere
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much of the DPN binding to ER (Stauffer et al. 2000). The binding affinity of DPN to
ERα is 0.25% of that of estradiol to ERα, or the conversion of 1000 µg/kg BW DPN to
2.85 µg/kg BW estradiol, a concentration that would not interfere much of the PPT binding
to ERα (Hartman et al. 2006). Progesterone from 15 mg/kg BW to 30 mg/kg BW was
shown to have synergistic effect with estrogen or PPT, therefore 20 mg/kg was selected for
this study (Visvader et al. 2003, Ferrandina et al. 2005).

Immunofluorescent (IF) and immunohistochemical (IHC) staining
IF and IHC assays were used to assess the BrdU-labeled cells and the expression
of ERα, ERβ, and cyclin D1 following conventional procedures. The sources for the
antibodies were as follows: ERα antibody (MC-20) from Santa Cruz Biotechnology, ERβ
(14C8) and BrdU antibodies from Abcam, cyclin D1 antibody (DCS-6) from Fisher
Scientific/Pierce. For IF staining, Alexa Fluor 488 (Invitrogen) was used for green
fluorescence, Rhodamine Red (Jackson ImmunoResearch) was used for red fluorescence,
and DAPI contained in Mounting Medium (Vector Lab) was used for nucleus staining to
give blue fluorescence. For IHC staining, VECTASTAIN Elite ABC Kit was used
following the manufacturer’s procedure. DAB (3, 3’-diaminobenzidine) was used as the
peroxidase substrate to develop brown color and Hematoxylin QS was used for
counterstaining. Antigen retrieval was carried out by microwaving (700 W) slides in 10
mM citrate buffer (pH 6.0), ERα and BrdU for 11 min, ERβ for 25 min, and cyclin D1 for
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20 min. ERα antibody was used at 1:200 dilution, ERβ antibody at 1:40 dilution, BrdU
antibody at 1:150 dilution, and cyclin D1 antibody at 1:80 dilution. Paraffin sections
without incubation with primary antibody were used as negative control of staining;
sections from ovary-intact tissues were used as positive control of staining.
Immunostaining slides were examined under Olympus BX50 Fluorescence Microscope
connected with the Optronics MagnaFire digital camera (Microscopy Imaging Center,
UVM). Images were taken with Optronics MagnaFire software and Adobe Photoshop was
used for further processing of the digital images.
The NIH software Image J was used for cell counting. For each mammary gland,
at least 250 ductal epithelial cells and 500 lobular/ alveolar bud epithelial cells were
counted. For the uterine endometrium of most rats, at least 400 luminal epithelial cells and
200 glandular epithelial cells were counted. For IHC images of cyclin D1 staining, the
staining was assigned at four levels, level 0 is unstained, level 1 is weak staining, level 3
is intensive staining, and level 2 is between level 1 and level 3 for moderate staining. Cells
with staining levels 2 and 3 were counted as positive staining cells, and cells with staining
levels 0 and 1 were counted as negative staining cells.

RNA isolation and quantitative real-time PCR assay
Total RNA was extracted with Trizol reagent (Invitrogen) and further purified with
RNeasy Kit (Qiagen). Two micrograms of RNA from each sample was used for reverse
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transcription with SuperScript III (Invitrogen). TaqMan probes for amphiregulin (Areg)
and β-actin labeled with FAM dye were purchased from Applied Biosystems (ABI).
Quantitative real-time PCR was performed for amphiregulin and β-actin (endogenous
control) using TaqMan gene expression assay (ABI) on an ABI 7500 real-time PCR System.
PCR for RNA from each sample was performed in duplicate and the average Ct from each
sample was used for further calculation. The relative gene expression of amphiregulin
transcripts were calculated using the 2 (−∆∆Ct) method. (Saville et al. 2000)

Statistical analysis
Statistical significance among different groups of animals was assessed by one-way
ANOVA. Post hoc Tukey’s HSD test was used for pairwise multiple comparisons to
determine which groups differ, with the significance level (alpha) set as 0.05. A p value
less than 0.05 was considered significant.
Results

Expression of ERα and ER in the mammary gland and uterine endometrium of OVX
rats
The expression patterns of ERα and ER in the mammary gland and uterus of OVX
rats were determined by immunofluorescent (IF) and immunohistochemical (IHC) staining,
respectively (Fig. 1). In the mammary gland of OVX rats, ERα was detected in more than
50% of luminal epithelial cells in the lobular and ductal structures (Fig. 1). In comparison
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to that of the ovary-intact rats, the mammary gland of ovariectomized rats showed more
cells with ERα expression but the staining intensity was weaker (Fig. 1, and data not
shown). ER was detected in almost all mammary epithelial cells with strong staining, and
ER-staining was also detected in some stromal cells in the mammary gland (Fig. 1). In
the uterus of OVX rats, ERα was detected in almost all endometrial luminal epithelial cells,
glandular epithelial cells, and stromal cells; the staining intensity in the epithelial cells was
much stronger than that in the stromal cells (Fig. 1). ER expression was detected mainly
in the endometrial luminal epithelial cells and glandular epithelial cells (Fig. 1). These data
confirmed that both ERα and ER were expressed in the mammary gland and uterus of
OVX rats.

DPN counteracts the proliferative effect of PPT in the mammary gland
To determine the effect of ERα and/or ER activation on mammary cell
proliferation, OVX rats were treated with ERα-selective agonist PPT alone, ER-selective
agonist DPN alone, or PPT and DPN combined. Mammary cell proliferation rate was
determined by the percentage of BrdU-labeled cells in different groups of rats. In
comparison to the control group, PPT treatment significantly increased mammary
epithelial cell proliferation rate in both ductal and lobular structures (Fig. 2). DPN
treatment slightly decreased the percentage of BrdU-labeled mammary epithelial cells;
statistically, the percentage of BrdU labeled cells in lobules and total cells (ducts and
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lobules combined) were significantly different from that of control rats (Fig. 2). In the
PPT/DPN group treated with PPT and DPN to activate both ERα and ER, mammary cell
proliferation rate was significantly lower than that of the PPT group but was not
significantly different from that of the control group (Fig. 2). Cyclin D1 expression was
evaluated to confirm the effect of PPT and/or DPN on mammary gland cell proliferation.
In the mammary glands of the control group and the DPN group, the percentages of cells
with moderate and intensive staining for cyclin D1 were very low (Fig. 3). Consistent with
the BrdU-staining data, PPT significantly increased the percentage of cells with moderate
and intensive staining for cyclin D1 (Fig. 3). In the mammary glands of the PPT/DPN
group, the percentage of cells with moderate and intensive staining for cyclin D1 was
similar to that of the control group and the DPN group, indicating that PPT-induced cyclin
D1 expression was suppressed by DPN (Fig. 3). Collectively, these data indicate that
activation of ERα by PPT but not activation of ER by DPN leads to increased mammary
cell proliferation, and that the proliferative effect of PPT on mammary cell proliferation
can be suppressed by DPN.

Inhibition of PPT induced amphiregulin expression by DPN in the mammary gland
In the mammary gland, ERα mediates cell proliferation by paracrine regulation and
the epidermal growth factor (EGF) family member amphiregulin plays critical role in the
paracrine action of ERα (Visvader et al. 2003, Mallepell et al. 2006, Ciarloni et al. 2007).
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Consistent with its estrogenic activity to promote cell proliferation as shown above, PPT
significantly increased amphiregulin expression (Fig. 4). DPN alone did not affect much
of amphiregulin expression; when co-administered with PPT, PPT induced amphiregulin
increase was significantly reduced by DPN in the PPT/DPN group (Fig. 4). These data
suggest that the inhibitory effect of DPN on PPT-induced mammary cell proliferation may
be mediated by suppression of amphiregulin expression.

DPN does not inhibit the estrogenic activity of PPT in the uterus
Uterine wet weight (UWW) and morphology were used to determine the
uterotrophic effect of PPT and DPN (Fig. 5A, and data not shown). In the OVX control
group, the uterus was very thin in diameter. Consistent with other studies (Couse et al.
1999, Persson et al. 1999, Harris et al. 2002, Frasor et al. 2003, Tilli et al. 2003, Hartman
et al. 2006, Wegorzewska et al. 2008), PPT treatment increased uterine diameter and
uterine wet weight, whereas uterus morphology and UWW in the DPN group were very
similar to that of the control group (Fig. 5A). Co-administration of DPN with PPT did not
inhibit or enhance PPT’s effect on UWW (Fig. 5A). Immunostaining of BrdU-labeled cells
was used to determine endometrial cell proliferation rate in different groups of rats (Fig.
5B and C). In comparison to the control group, PPT treatment group showed significantly
higher percentage of BrdU-labeled endometrial luminal and glandular cells (Fig. 5B and
C). DPN treatment did not affect the percentage of BrdU-labeled endometrial luminal and
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glandular cells (Fig. 5B and C). When PPT and DPN were co-administered in the PPT/DPN
group, PPT-increased cell proliferation was not inhibited by DPN (Fig. 5B and C). These
data are consistent with that the estrogenic activity in the uterus is mediated by ERα and
that ER-selective agonist DPN had little effect on the estrogenic activity of ERα-selective
agonist PPT in the uterus (Persson et al. 1999, Harris et al. 2002, Berry et al. 2003, Frasor
et al. 2003, Sánchez-Criado et al. 2004, Wegorzewska et al. 2008, Bliedtner et al. 2010).
The estrogenic activity of PPT in the uterus is opposed by progesterone and the
opposing function of progesterone in the uterus is not affected by DPN
The adverse effect of estrogenic activity on uterine endometrium can be opposed
by progestins (Persson et al. 1999, Frasor et al. 2003). Consistent with that the estrogen
action in the uterus is mediated by ERα, we found that the estrogenic activity of ERαagonist PPT can be opposed by progesterone (Fig. 5). The UWW and the percentage of
BrdU-labeled endometrial epithelial cells in the PPT/P4 group were significantly lower
than that of the PPT group (Fig. 5). UWW and the percentage of BrdU-labeled endometrial
epithelial cells in the PPT/P4/DPN group were similar to that of the PPT/P4 group (Fig. 5).
These data indicate that progesterone has opposing effect on PPT in the uterus tissues and
DPN does not affect the opposing function of progesterone.
The inhibitory function of DPN in mammary cell proliferation remains effective when
used together with PPT and progesterone
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Progestins when used alone have little effect on mammary cell proliferation;
however, progestins and estrogen have synergistic effect on mammary cell proliferation
and progestins also have synergistic effect with PPT in promoting mammary gland end bud
development (Hofseth et al. 1999, Regan et al. 2006, Ciarloni et al. 2007, Zhao et al. 2008).
Consistently, we found that the percentage of BrdU labeled mammary proliferating cells
was significantly higher in the PPT/P4 group than that of the PPT group (Figs. 2 and 6).
To determine whether the inhibitory effect of DPN on mammary cell proliferation is
affected by progesterone, DPN was co-administered with PPT/P4. The percentage of BrdU
labeled mammary cells in the PPT/P4/DPN group was significantly lower than that of the
PPT/P4 group, indicating that the inhibitory function of DPN was still effective when coadministrated with PPT/P4 (Fig. 6).
Discussion
Mammary gland and uterine endometrium are classic estrogen regulated
organs/tissues and the estrogen action is mediated mainly by ERα (Couse et al. 1999,
Hanahan et al. 2000, Harris et al. 2002, Berry et al. 2003, Herynk et al. 2004, Hartman et
al. 2006, Mallepell et al. 2006, Tan et al. 2009). Excessive estrogenic activity, such as
estrogen-based postmenopausal hormone replacement therapy, exposure to environmental
endocrine disruptive agents with estrogenic activity, early menarche or late menopause, is
associated with increased risk for breast cancer and/or endometrial cancer (Russo et al.
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1998, Waard et al. 2005, Shanle et al. 2010). Accumulating evidence indicates that ER
may function as a tumor suppressor and therefore can be exploited for cancer prevention
and therapy (Harris 2007, Deroo et al. 2010, Warner et al. 2010). However, in vivo animal
model studies on the role of ER and its interaction with ERα in mammary cell
proliferation and tumorigenesis are very limited and the expected tumor suppressor
function was not observed in the studies using ER-selective agonists BAG and ERB-041
(Harris et al. 2003, Helguero et al. 2005, Crabtree et al. 2006). It is unknown whether ERB041 or other ER-selective agonists have additive/synergistic or antagonistic effect with
ERα-selective agonist PPT in mediating mammary cell proliferation. In this study, we used
ER-selective agonists PPT and DPN to activate ERα and ER separately in an OVX rat
model. We demonstrated for the first time that the estrogenic activity of PPT in the
mammary gland, including cell proliferation and amphiregulin expression, can be opposed
by an ER-selective agonist in an animal model. We further showed that the estrogenic
activity of PPT in the uterus can be opposed by progesterone, and that DPN and
progesterone do not interfere with each either for their respective opposing functions in the
mammary gland and uterus. These findings indicate that the adverse effect of ERαmediated estrogenic activity in different organs/tissues can be opposed by different drugs
via different mechanisms, which may be explored for the development of better hormone
replacement therapy regimen with less risk for breast and endometrial cancer.
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The differential effect of DPN on the estrogenic activity of PPT in the mammary
gland and uterus supports that the effect of DPN activated ER on target cells is cell type
dependent. In addition, the effect of ER on cellular activities of target cells is ligand type
dependent and the results from ER-selective agonists including DPN may not represent
the physiological role of ER bound to estrogen (Harris 2006, Harris 2007, Paruthiyil et al.
2009, Deroo et al. 2010). The effect of DPN on mammary cell proliferation in this study is
quite different from that of the ER-selective agonist BAG in the study by Cheng et al.
using an OVX mouse model (Cheng et al. 2004). It is unlikely that the difference is caused
by different rodent species, but it will be valuable to evaluate ER-selective agonists in
more than one species. It is more likely that different ER-selective agonists including
DPN and BAG may exert different effects; in that case, it will be valuable to determine
whether other ER-selected agonists besides DPN have anti-proliferative function in the
mammary gland.
The uterotrophic activity of PPT and several ER-selective agonists has been well
studied in different rodent models. In all these models, PPT has been shown with estrogenic
activity to increase uterine wet weight or to stimulate endometrial cell proliferation (Frasor
et al. 2003, Harris 2007, Bliedtner et al. 2010). For the ER-selective agonists evaluated
for uterotrophic activity, 8-VE2 is the only one known with uterotrophic activity
(Helguero et al. 2005, Harris 2007). In the OVX rodent models, DPN does not have
uterotrophic activity (Wegorzewska et al. 2008, Engdahl et al. 2010). Data on whether the
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uterotrophic activity of PPT can be suppressed by DPN is inconsistent in different animal
models. In the OVX model, our data are consistent with that DPN does not suppress the
uterotrophic activity of PPT (Sánchez-Criado et al. 2004). In ArKO (aromatase knock-out)
and ovary intact immature mouse models, DPN does not have uterotrophic activity but may
have some inhibitory activity and reduces the estrogenic activity of PPT (Frasor et al. 2003,
Bliedtner et al. 2010). From these different models, it is clear that DPN does not have
uterotrophic activity and may instead inhibit the ERα-mediated uterotrophic activity to a
certain extent. The reason why DPN has a more pronounced suppressive effect on PPT
activity in the mammary gland vs. the uterus is not clear. It could be related to the relative
expression levels of ER or the relative ratios of ERα/ER in these two types of tissues. It
is worth noting that the relative expression patterns of ERα and ER are different in these
two types of tissues, which might also account for the differential effect of DPN in these
two types of tissues. As shown in Fig. 1, ER expression is more widespread than ERα in
the mammary gland; in the uterine endometrium, ERα expression is more widespread than
ER. The mammary gland and uterine endometrium respond differently to Tamoxifen,
indicating that the cellular contexts, such as coactivators or corespressors, might be
different in these two types of tissues that may also be related to the differential effect of
DPN (Jordan et al. 2007).
In the PPT/DPN group of rats in this study, the estrogenic activity of PPT in the
mammary gland is almost completely abrogated by DPN, as determined by mammary cell
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proliferation rate and expression of cyclin D1 and amphiregulin. The mammary cell
proliferation rate in the PPT/P4/DPN group is significantly lower than that in the PPT/P4
group, indicating that ERα-mediated activity that functions synergistic with progesterone
is significantly inhibited by DPN. However, the mammary cell proliferation rate in the
PPT/P4/DPN group is significantly higher than that in the control and PPT/DPN groups,
and even a little higher than the PPT group. These data indicate that when co-administered
with PPT/P4, PPT activated ERα activity is not completely blocked by DPN. Further
studies are needed to determine whether the inhibitory function of DPN is dose-dependent
and whether the inhibitory function of DPN can be further increased at other doses.
ERα-mediated activity is believed to be responsible for the increased risk for breast
cancer and endometrial cancer in women under HRT. As shown in this study using the
OVX postmenopausal rat model, ERα-mediated estrogenic activity activated by PPT in the
mammary gland and uterus can be differentially opposed by DPN and progesterone,
respectively. It will be interesting to determine whether a regimen containing DPN such as
PPT/DPN/progestin is a better option than the estrogen-plus progestin regimen. When
considering inclusion of DPN or ER-selective agonist in the hormone replacement
therapy regimen, at least two types of effects need to be considered. The first concern is
whether ER-selective agonist has adverse effects in different organs/tissues. The other
concern is that whether some of the beneficial effects of estrogenic activity are abolished
or some of the adverse effects of estrogenic activity are enhanced. Based on the reported
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animal model studies involving many organ systems, it seems that PPT and DPN might be
good candidates with regards to the beneficial vs. adverse effects. Here we will briefly
discuss the effects on the mammary gland, uterine endometrium, hot flashes, and bone
metabolism. As aforementioned, DPN can inhibit the adverse effect of PPT in the
mammary gland and DPN has no adverse effect on uterine endometrium. With regards to
hot flashes, both PPT and DPN have been shown to prevent hot flashes in rodent models
(Harris et al. 2002, Liu et al. 2002). For bone metabolism, bone sparing activity is found in
PPT but not found in several ER-selective agonists including ERB-041; the effect of DPN
on bone metabolism is unknown (Berry et al. 2003, Harris 2007). Further studies will be
needed to determine the effect of DPN on bone metabolism and its effect on the bone
sparing activity of PPT. In summary, these functional studies of DPN in animal models
suggest that DPN merits consideration for the development of better hormone replacement
therapy regimen.
Conclusion
Estrogen-based postmenopausal hormone replacement therapy increases the risk
for breast and uterine endometrial cancers; estrogen action in the mammary gland and
endometrium is mediated mainly by ERα (Couse et al. 1997, Couse et al. 1999, Persson et
al. 1999, Banks et al. 2003, Cheng et al. 2004, Paruthiyil et al. 2004, Deroo et al. 2006,
Mallepell et al. 2006, Harris 2007). In this study using an ovariectomized postmenopausal
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rat model and the ERα-selective agonist PPT and ER-selective agonist DPN, we provide
in vivo evidence that ERα-mediated estrogenic activity in the mammary gland can be
opposed by ER-selective agonist DPN. Suppressing PPT-induced amphiregulin
expression by DPN may account for its opposing function in mammary gland cell
proliferation. The estrogenic activity of ERα-agonist PPT in the uterus can be opposed by
progesterone. These findings indicate that the adverse effect of ERα-mediated estrogenic
activity in different organs can be opposed by different mechanisms, which may be
explored for the development of better hormone replacement therapy regimen with less
risk for breast and endometrial cancer.
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Figures

Figure 1. Immunostaining of ERα and ER in the mammary gland and uterine
endometrium of ovariectomized rats.
Five to six week old rats were ovariectomized (OVX), and mammary gland and uterus
tissues were harvested two weeks after OVX. The expression pattern of ERα was
determined by IF staining (green fluorescence, top panels). Cell nuclei were counterstained
with DAPI (blue fluorescence). Images of ERα staining and DAPI staining were overlaid
to show the localization of ERα-staining cells (middle panels). The expression pattern of
ER was determined by IHC staining with DAB as substrate to give brown color (bottom
panels). In the mammary gland, ERα staining was detected in more than 50% of luminal
epithelial cells; ER was expressed in almost all epithelial cells and some stromal cells. In
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the endometrium, ERα was detected in almost all epithelial cells and stromal cells; ER
expression was detected mainly in the luminal and glandular epithelial cells. DE, ducts;
ELE, endometrial luminal epithelial cells; EGE, endometrial glandular epithelial cells; LE,
lobules. Magnification, 400×.
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Figure 2. DPN counteracts the proliferative effect of PPT in the mammary gland of
OVX rats.
OVX rats were rested for two weeks before treatment for 3 days with DMSO (control),
DPN, PPT, PPT and DPN (PPT/DPN), respectively. BrdU was injected concurrently with
each drug administration to label proliferating cells. (A) Percentage of BrdU-labeled
proliferation cells in the mammary gland of different groups of rats. Mammary epithelial
cells in ductal and lobular structures were counted separately, and the total is the
combination of ductal and lobular cells. DPN slightly decreased mammary cell
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proliferation. PPT significantly increased mammary epithelial cell proliferation. When coadministered with PPT, DPN significantly decreased mammary cell proliferation caused
by PPT. Data are shown as means ± SD. The p values are as follows: 0.45 for DPN vs.
control in the ducts, 0.03 for DPN vs. control in the lobules and totals; <0.001 for PPT vs.
control in the ducts, lobules, and total; 0.023 for PPT&DPN vs. PPT in the ducts, and
<0.001 for PPT&DPN vs. PPT in the lobules and total (*p < 0.05; **p < 0.01; ***p <
0.001). (B) Representative microimages showing BrdU-labeled proliferation cells in the
mammary ductal and lobular structures of different groups of rats. BrdU labeled cells were
detected by immunofluorescent staining with BrdU stained with red fluorescence; nuclei
were counterstained with DAPI to give blue fluorescence. Images of BrdU staining and
DAPI staining were merged to show the location of BrdU-labeled cells. Magnification, 400
×.
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Figure 3. DPN inhibits PPT induced cyclin D1 expression in the mammary gland.
(A) Percentage of cells with moderate and intensive staining for cyclin D1 in the mammary
gland of different groups of rats. Mammary epithelial cells in ductal and lobular structures
were counted separately, and the total is the combination of ductal and lobular cells.
(B) Cyclin D1 was detected by immunohistochemical staining using DAB as the substrate
(brown color) and hematoxylin for counterstaining (blue color). Cells were counted as
unstained, weakly stained, moderately stained, and intensively stained for cyclin D1. Cells
with moderate or intensive staining were calculated as cyclin D1 staining cells and the
percentage of those cells were shown in the graph as means ± SD. PPT significantly
increased the percentage of cyclin D1 staining cells. When co-administered with PPT, DPN
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significantly decreased the percentage of cyclin D1 staining cells caused by PPT. The p
values are as follows: 1.00 for DPN vs. control in the ducts, lobules, and totals; 0.002 for
PPT vs. control in the ducts, lobules, and totals; 0.001 for PPT&DPN vs. PPT in the ducts,
lobules, and totals (*p < 0.05; **p < 0.01). (B) Representative cyclin D1 IHC staining
images of ductal and lobular structures in the mammary gland of the four groups of rats.
Cells with intensive cyclin D1 staining (arrows) were found in the mammary gland treated
with PPT and barely observed in the mammary gland of the other three groups (control,
DPN, PPT/DPN). Magnification, 400×.
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Figure 4. DPN inhibits PPT induced amphiregulin expression in the mammary gland.
RNA levels of amphiregulin were determined by quantitative real-time RT-PCR; -actin
was used as internal control. PPT but not DPN significantly increased amphiregulin
expression. Amphiregulin expression in the PPT/DPN group was significantly lower than
that in the PPT group. Data are shown as means ± SD. The p values are as follows: 0.003
for PPT vs. control; 0.013 for PPT&DPN vs. PPT (*p < 0.05; **p < 0.01).
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Figure 5. The estrogenic activity of PPT in the uterus is opposed by progesterone but
not by DPN.
(A) Uterine wet weight (UWW) in different groups of rats. PPT but not DPN had
uterotrophic activity. The uterotrophic activity of PPT was opposed by progesterone but
not by DPN. Data are shown as means ± SD. ***p < 0.001 for the PPT group vs. the
control group. (B) Percentage of BrdU-labeled endometrial luminal and glandular
epithelial cells. PPT but not DPN significantly increased endometrial luminal and glandular
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epithelial cell proliferation. The effect of PPT on endometrial epithelial cell proliferation
was opposed by progesterone but not by DPN. Data are shown as means ± SD. The p
values are as follows: <0.001 for PPT vs. control in luminal epithelial cells, 0.003 for PPT
vs. control in glandular epithelial cells; 0.014 for PPT/P4 vs. PPT in luminal epithelial cells,
and 0.078 for PPT/P4 vs. PPT in glandular epithelial cells (*p < 0.05; **p < 0.01; ***p <
0.001). (C) Representative microimages showing BrdU-labeled proliferation cells in
endometrial luminal and glandular cells. BrdU-labeled cells were detected by
immunohistochemical staining using DAB as substrate (brown color) and hematoxylin for
counterstaining. ELE, endometrial luminal epithelial cells; EGE, endometrial glandular
epithelial cells. Magnification, 400×.
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Figure 6. DPN inhibits mammary cell proliferation induced by PPT and progesterone.
(A) Percentage of BrdU-labeled mammary epithelial cells. See Fig. 2 to compare with other
groups of rats. PPT and progesterone (P4) were synergistic in promoting mammary
epithelial cell proliferation. When co-administered with PPT/P4, DPN significantly
decreased mammary cell proliferation caused by PPT/P4. Data are shown as means±SD.
The p values are as follows: <0.001 for PPT/P4 vs. PPT in the ducts, lobules, and totals;
0.02 for PPT/P4 & DPN vs. PPT/P4 in the ducts, <0.001 for PPT/P4 & DPN vs. PPT/P4 in
the lobules and totals (*p < 0.05; ***p < 0.001). (B) Representative microimages showing
BrdU-labeled proliferation cells in the mammary ductal and lobular structures. BrdUlabeled cells were detected by immunofluorescent staining with BrdU stained with red
fluorescence; nuclei were counterstained with DAPI to give blue fluorescence. Images of
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BrdU staining and DAPI staining were merged to show the location of BrdU-labeled cells.
Magnification, 400×.
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CHAPTER 3: Overexpression of estrogen receptor beta
inhibits mammary epithelial cell proliferation in Sprague
Dawley rats
Abstract
The function of estrogen is mediated by two types of estrogen receptors, estrogen
receptor α (ERα) and estrogen receptor β (ERβ). The mitogenic action of estrogen in the
mammary gland is mediated by mainly by ERα, whereas the function of ERβ is less
understood. Accumulating evidence indicates that ERβ is able to antagonize the activity of
ERα in many cellular processes. In the previous studies, we demonstrated that activation
of endogenous ERβ can counteract the mitogenic action of ERα in the mammary gland. In
many breast cancers, ERβ expression is decreased and overexpression of ERβ in breast
cancer cell lines decreased cell proliferation, indicating that high levels of ERβ may inhibit
cell proliferation. In present study, we used lentiviral infection to overexpress ER in
normal rat mammary gland and determined its effect on mammary cell proliferation. We
first evaluated the expression of endogenous ERα and ERβ in the mammary gland and the
mammary cell proliferation rate during the estrous cycles. In the proestrus phase, ERα was
detected in about 20% of mammary epithelial cells; in the diestrus phase, no ERα staining
was detected in mammary epithelial cells. In the proestrus phase, ER was expressed in
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more than 50% of mammary epithelial cells and ER staining was found in some stromal
cells as well. In the diestrus phase, ER was expressed in about 20% of mammary epithelial
cells, the staining intensity of ERβ was much weaker than that in the proestrus phase. In
the mammary glands infected with lentivirus to overexpress ERα or ER, ERα
overexpression significantly increased cell proliferation in diestrus phase, whereas ER
overexpression significantly decreased cell proliferation in both proestrus and diestrus
phases. These data provided the first in vivo evidence that mammary cell proliferation is
decreased by high levels of ER expression, supporting that ER is a negative regulator of
mammary cell proliferation. Decreased levels of ERβ or the ratio of ERβ/ERα may
contribute breast cancer initiation and progression.

Introduction
Development of the mammary gland occurs in distinct stages, embryonic, neonate,
puberty, pregnancy, lactation, and involution (Visvader et al. 2003). The mammary gland
only contains simple and rudimentary ducts at birth (Sinha et al. 1969). During the puberty
stage, due to a large increase in systemic hormones, the mammary gland cells undergo
rapid proliferation, which contributes to extensive ductal branching and elongation (Ruan
et al. 1995, Brisken et al. 1998, Silberstein 2001, Mulac-Jericevic et al. 2003). However,
the full development and differentiation of mammary gland can be completed only after
pregnancy and lactation (Anderson et al. 1990).
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Mammary gland cell proliferation, differentiation, and apoptosis undergo dynamic
alterations in different phases of the estrous cycle (Schedin et al. 2000). It has been
demonstrated by the vast majority of studies that the highest mammary cell proliferation
rate is found in the luteal phase of the human menstrual cycle (Ferguson et al. 1981, Vogel
et al. 1981, Potten et al. 1988, Söderqvist et al. 1997). In mice and rats, the mammary cell
proliferation rate in the diestrus phase is several times higher than that in the proestrus
phase (Schedin et al. 2000, Fata et al. 2001). The data on whether alveolar and ductal
structures possess different cell proliferation rates are controversial. There is one study
showing that the proliferation rate was similar in the alveolar and ductal structures of
female breast tissue (Söderqvist et al. 1997). However, Fata and his colleagues found that
epithelial cell proliferation rate in the alveolar structure is significantly higher than that in
the ductal structure (Fata et al. 2001).
The development of mammary gland is regulated largely by systemic hormones,
including estrogen, progesterone, growth hormone, prolactin, oxytocin, glucocorticoids,
thyroid hormones, and insulin (Hadley et al. 2006). Estrogen, mainly produced by the ovary,
is perhaps the most important hormone in regulating mammary gland development (Berry
et al. 2003). Local administration of anti-estrogen into the mammary gland of mouse
inhibits mammary cell proliferation and simplifies the pattern of ductal branching
(Silberstein et al. 1994). Ovariectomized (the ovaries are removed) animals have reduced
mammary gland growth, which can be restored by exogenous estrogen application (Berry
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et al. 2003, Cheng et al. 2005). Estrogen also stimulates mammary gland development
indirectly by inducing the production of growth factors that play an important role in
regulating cell proliferation and differentiation (Mallepell et al. 2006, Ciarloni et al. 2007).
For example, amphiregulin, an epidermal growth factor receptor (EGFR) ligand required
for ductal elongation and side branching in the mammary gland, is an important paracrine
mediator of estrogen activity (Ciarloni et al. 2007).
The biological actions of estrogen are mediated by two types of estrogen receptors,
estrogen receptor α (ERα) and estrogen receptor β (ERβ) (Zhang et al. 2003, Zhao et al.
2008). Both types of estrogen receptors belong to the nuclear receptor superfamily and are
involved in the transcriptional regulation of their target genes (Green et al. 1986, Kuiper et
al. 1996, McDonnell et al. 2002). ERα is known as the primary estrogen receptor expressed
in mammary gland and its expression level is much higher than that of ERβ (Jensen et al.
2001, Pettersson et al. 2001, Shyamala et al. 2002). ERα is expressed only in epithelial
cells, it is not expressed in stromal or myoepithelial cells (Saji et al. 2000). In ERα knockout mice, the mammary glands remain rudimentary after birth and there is no further
growth in later stages of development, indicating that ERα is required for mammary gland
development (Bocchinfuso et al. 1997). ERα has been shown essential for the mitogenic
effect of estrogen on mammary gland cell proliferation both in vivo and in vitro
(Bocchinfuso et al. 1997, Tilli et al. 2003, Mallepell et al. 2006).
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Compared with ERα, ERβ is much less studied and its function is not fully
understood. ER expression has been detected in epithelial cells, stromal cells and
myoepithelial cells (Palmieri et al. 2002, Speirs et al. 2004). ERβ knock-out mice have
relatively normal mammary gland structures during puberty and are able to lactate
normally after pregnancy (Förster et al. 2002, Walker et al. 2004). However, the ER
knockout mice have delayed side branching in the puberty stage and the lobuloalveolar
structures are less developed during pregnancy, suggesting that ERβ is involved in
mammary cell differentiation and alveologenesis (Förster et al. 2002, Walker et al. 2004).
Unlike ERα, ER has been implicated as a negative regulator of cell proliferation in both
normal breast tissues and breast tumors (Lazennec et al. 2001, Liu et al. 2002, Visvader et
al. 2003, Paruthiyil et al. 2004, Helguero et al. 2005, Song et al. 2012). Introducing ERβ
into immortalized or breast tumor cell lines inhibits cell proliferation (Lazennec et al. 2001,
Liu et al. 2002, Visvader et al. 2003, Paruthiyil et al. 2004, Helguero et al. 2005). ERβ
overexpression has also been shown to inhibit cell proliferation and tumor growth in MCF7
and T47D xenograft tumors (Paruthiyil et al. 2004, Hartman et al. 2009). Moreover, ER
expression is found to be decreased or lost in many primary breast tumors and ER levels
are inversely correlated with the survival rate (Zhao et al. 2003, Girault et al. 2004,
Gruvberger-Saal et al. 2007, Honma et al. 2008). In chapter two of this dissertation, we
examined the mammary cell proliferation by using ERβ selective agonist DPN. We found
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that activation of ERβ inhibited cell proliferation in OVX rats. There is no report on
whether ERβ overexpression can inhibit mammary cell proliferation in vivo.
In present study, we further investigated whether the effect of ER on mammary
cell proliferation is affected by the expression levels of ER. We first evaluated the
expression of endogenous ERα and ERβ in the mammary gland and the mammary cell
proliferation rate during the estrous cycles. We demonstrated that mammary epithelial cell
proliferation rate is similar in alveolar and ductal structures. Overexpression of ERα
significantly increased cell proliferation in the diestrus phase. Overexpression of ER
significantly decreased cell proliferation in both proestrus and diestrus phases.
Amphiregulin gene expression is increased by overexpressing ERα but not ERβ. These
data provided the first in vivo evidence that mammary cell proliferation is decreased by
high levels of ER expression, supporting that ER is a negative regulator of mammary
cell proliferation.
Methods

Lentivirus Production
The cDNA of ERα and ERβ are the gifts from Dr. Yongkui Jing (Mount Sinai
School of Medicine) and Dr. Kenneth S. Korach (National Institute of Environmental
Health Science / National Institute of Health). EGFP and human ERα-IRES-EGFP cDNA
were subcloned into plenti6/V5-DEST of the ViraPower™ Lentiviral Expression System
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(Invitrogen,

Carlsbad,

CA).

Human

ER

cDNA

was

subcloned

into

pLVX_IRES_ZsGreen1 of the Lenti-X™ Lentiviral Expression Systems (Clontech, Palo
Alto, CA). Human ERα and ER cDNA instead of rat ERα and ER cDNA were used to
make lentivirus. The comparison of amino acid sequence is shown in figure 7. Human ERα
and rat ERα proteins have 88% amino acid identity. Human and rat ERβ share an overall
amino acid identity of 89%. 293FT (Invitrogen, Carlsbad, CA) cells were co-transfected
with the lentivirus plasmids and the packaging/helper plasmids for 62-72 hours following
the manufacturer’s instructions for production of lentiviruses. Generated lentiviruses in the
culture medium were collected and filtered through 0.45 m PVDF filter (Millipore,
Billerica, MA). Lentiviral stocks were concentrated using Lenti-X concentrator (Clontech,
Palo Alto, CA).

Animal Treatment and Sample Collection
All animal experimental procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of Vermont. Thirteen weeks old
virgin female Sprague-Dawley rats were purchased from Charles River Laboratories
(Senneville, Canada) and were housed with a 12-hour light and dark cycle with free access
to water and food. Thirty two rats were randomly assigned to four groups, the uninfected
control group, the EGFP group, the ERα overexpressing group and the ERβ overexpression
group. Rats were anesthetized first and the replication incompetent lentiviruses expressing
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EGFP or estrogen receptors were introduced via intraductal instillation to infect the
mammary gland cells. The tit was cut and the central duct of the 4th pair mammary gland
was injected with 20 μl of solution containing lentiviruses, polybrene (8 mg/ml) and fast
green (0.5 mg/ml) by using Hamilton syringe. Vaginal smear was used to determine the
estrous cycle 10 days (about two menstrual cycles) after the intraductal infusion. Four rats
in each group were sacrificed in pro-estrous stage and 4 rats in diestrus stage. Two hours
before sacrifice, rats received an intraperitoneal infusion of 5-bromo-2'-deoxyuridine
(BrdU) (2 mg/100 g body weight). Half of harvested tissue was fixed in neutral formalin
for 48 hours before being processed for paraffin embedding (Pathology lab, Fletcher Allen
Health Care, VT) and the other half was snap-frozen and stored in liquid nitrogen for RNA
isolation.

Western Blot and Slot Blot
Rat mammary gland tissue samples were homogenized using a Dounce
homogenizer, on ice, in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5 mM
sodium pyrophosphate, 1 mM sodium β-glycerophosphate, 5 mM NaF, 1 mM Na3VO4, 1
mM phenylmethylsulfonyl fluoride, 10% Nonidet P40, and protease inhibitor mixture
(Roche Molecular Biochemicals, Indianapolis, IN)). Fat tissue and cell debris were
removed by centrifugation (14,000 × g for 15 min at 4°C). Cell lysates were sonicated and
cellular debris were removed by centrifugation (14,000 × g for 15min at 4°C). The protein
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concentration was determined using the BioRad DC protein assay reagent (BioRad,
Hercules, CA) , and 150 μg protein from each treatment were loaded on 10% SDS-PAGE
gel and then transferred onto PVDF membranes after electrophoresis (Millipore, Bedford,
MA). For immunoblotting, the membranes were blocked with Tris-Buffered Saline and
Tween 20 (TBST) containing 5% non-fat milk and 3% Bovine Serum Albumin (BSA) for
1 hour at room temperature. Primary antibody was used at 1:200 dilution and incubated in
TBST containing 3% BSA overnight at 4C. Membranes were washed 4 times, 7 minutes
each with TBST before blotting with second antibodies. Horseradish Peroxidase (HRP)conjugated secondary antibody was diluted at 1:10,000 and incubated with membranes in
TBST containing 5% non-fat milk for 1 hour at room temperature. The Western
Lightning™ Chemiluminescence Reagent Plus (PerkinElmer, Waltham, MA) was used to
detect protein immobilized on the membrane.
Same amount of protein (275 μg) from each treatment was transferred to
nitrocellulose membrane using the Miniflold II slot-blot system (Schleicher & Schuell,
Keene, NH). The membrane was hybridized with anti-ZsGreen antibody (Clontech, Palo
Alto, CA) and followed by HRP-conjugated secondary antibody. The Western Lightning™
Chemiluminescence Reagent Plus (PerkinElmer, Waltham, MA) was used to detect protein
immobilized on the membrane. Protein lysate from ERβ-ZsGreen lentivirus infected
293FT cells was used as positive control.
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Immunofluorescent (IF) and Immunohistochemical (IHC) Staining
293FT cells grown on glass coverslips were briefly washed with ice-cold
Dulbecco's PBS and fixed with cold 4% paraformaldehyde containing 0.01% Triton X-100
for 25 min on ice. After washing once briefly with PBS-T (Dulbelcco's PBS containing
0.01% Triton X-100), the cells were treated with 0.05% Triton x-100 in PBS for 10 min
for permeabilization. The cells were washed once briefly with PBS-T, followed by
blocking in PBS-T containing 5% normal serum and 50 mM NH4Cl for 30 min at room
temperature. The cells were then incubated with primary antibodies diluted in PBS-T
containing 1% normal serum. Anti-ERα antibody was diluted at 1:200, and anti-ERβ at
1:40. After overnight incubation at 4°C, the cells were washed four times with PBS-T, 7
min each time. Then the cells were incubated for 1 hour at room temperature with
fluorescent dye-conjugated secondary antibodies (1:200) in PBST containing 1% normal
serum. The cells were washed 4 times with PBS-T, 7 min each time before mounted on
slides with VectoShield with DAPI (Vector Lab, Burlingame, CA).
Fixed and embedded mammary tissues were cut into 5-μm sections and mounted
onto gelatin-coated slides. IHC and IF assays were used to assess the BrdU-labeled cells
and the expression of ERα and ERβ following conventional procedures. The sources for
the antibodies were as follows: ERα antibody (MC-20) from Santa Cruz Biotechnology,
ERβ (14C8) and BrdU antibodies from Abcam, cyclin D1 antibody (DCS-6) from Fisher

138

Scientific/Pierce. For IF staining, Alexa Fluor 488 (Invitrogen, Billerica, MA) was used
for green fluorescence, Rhodamine Red (Jackson ImmunoResearch Laboratories, West
Grove, PA) was used for red fluorescence, and DAPI contained in Mounting Medium
(Vector Lab, Burlingame, CA) was used for nucleus staining to give blue fluorescence. For
IHC staining, VECTASTAIN Elite ABC Kit (Vector Lab, Burlingame, CA) was used
following the manufacturer’s procedure. DAB (3, 3’-diaminobenzidine; Vector Lab,) was
used as the peroxidase substrate to develop brown color and Hematoxylin QS (Vector Lab,
Burlingame, CA) was used for counterstaining. Antigen retrieval was carried out by
microwaving (700 W) slides in 10 mM citrate buffer (pH 6.0), ERα and BrdU for 11 min
and ERβ for 25 min. The slides were washed once briefly with PBS-T, followed by
blocking in PBS-T containing 5% normal serum for 1 hour at room temperature. ERα
antibody was used at 1:200 dilution, ERβ antibody at 1:40 dilution and BrdU antibody at
1:150 dilution. Immunostaining slides were examined under Olympus BX50 Fluorescence
Microscope (Microscopy Imaging Center, UVM).
Images were taken with QImaging Retiga 2000R digital camera (QImaging, Surrey,
BC, Canada) and Adobe Photoshop was used for further processing of the digital images.
The brightness, contrast and exposure level were adjusted for cell counting.
The software Image J (NIH, Bethesda, MD) was used for cell counting. For each
mammary gland, at least 500 ductal epithelial cells and 600 lobular epithelial cells were
counted. For IHC images of BrdU staining, based on the staining intensity, the staining
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was assigned at four levels. The level 0 is unstained, level 1 is weak staining, level 2 is
moderate and level 3 is intensive staining. The cells with staining levels 0 and 1 were
counted as BrdU negative staining cells and the cells with staining levels 2 and 3 were
counted as BrdU positive staining cells.

RNA Isolation and Quantitative Real-Time PCR Assay
Total RNA was extracted with Trizol reagent (Invitrogen, Billerica, MA) and
further purified with RNeasy Kit (Qiagen, Valencia, CA). The concentrations of isolated
RNA were measured with a NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE). Two μg of total purified RNA was reverse transcribed using SuperScript
III reverse transcriptase (Invitrogen, Billerica, MA). TaqMan Gene Expression Assay Mix
(Applied Biosystems, Foster City, CA) were used to quantify the mRNA expression levels
of amphiregulin (Areg) and β-actin (endogenous control). Real-time PCR for RNA from
each sample was performed in duplicates in a 20 μl reaction system containing 10μl
Universal PCR Master Mix (Applied Biosystems, # 4352042), 1 μl TaqMan Assay Mix,
and 9 μl diluted cDNA. The reaction conditions for amplification of DNA were 50 °C for
2 min, 95 °C for 10 min and 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The average
Ct from each sample was used for further calculation. The relative gene expression of
amphiregulin transcripts were calculated using the 2(-∆∆Ct) method (Livak et al. 2001).
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Statistical Analysis
All statistical analyses were performed using the JMP software (SAS, Cary, NC).
One-way analysis of variance (ANOVA) analysis followed by Tukey's post hoc test were
carried out on collected data and p value less than 0.05 was considered statistically
significant.
Results

Expression of ERα and ERβ in the Mammary Gland during Estrous Cycle
We compared the expression pattern of ERα and ERβ in the rat mammary gland
in the proestrus phase with that in the diestrus phase. For the ERα staining, 20% of
mammary epithelial cells were stained positive in the proestrus phase and there was ERα
staining in the diestrus phase; these data are consistent with the data by other studies (Fig.
8). For the ER staining, ER staining was found in more than 50% of mammary epithelial
cells in the proestrus phase, but only about 20% of mammary epithelial cells showed ERβ
staining in the diestrus phase (Fig. 8). The staining intensity of ERβ was much weaker in
the diestrus phase than that in the proestrus phase (Fig. 8). In addition, ERβ staining was
detected in some stromal cells in both the proestrus and diestrus phases, and no significant
difference was observed in the fraction of such ERβ positive stromal cells in the two phases.
These results first confirmed that ERα is only expressed in the proestrus phase and further
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demonstrated that ERβ is expressed in both the proestrus and diestrus phases, and ERβ
expression level was lower in the diestrus phase than that in the proestrus phase.

Overexpression of ERα and ERβ in Mammary Gland by Lentiviral Infection
We first infected 293FT cell with ERα – EGFP lentivirus. ERα and EGFP coexpressed in the all the infected cells (Fig. 9). EGFP and ERβ – ZsGreen lentiviruses were
also tested in 293FT cell. EGFP expressed in the infected cells and ERβ and ZsGreen coexpressed in all infected cells (data not shown). Then we infected rat mammary glands and
determined the infection efficiency by evaluating the reporter gene expression levels in
each group. The expression of reporter gene EGFP was analyzed by western blot (Fig.
10A), and the expression of reporter gene ZsGreen was analyzed with slot blot (Fig. 10B).
As expected, expression of EGFP was found in the EGFP group and the ERα group, but
not in the uninfected negative control group or the ERβ group (Fig. 10A). Protein lysate
from ERβ-ZsGreen lentivirus infected 293FT cells was used as positive control for the slot
blot to analyze the expression of ZsGreen (Fig. 10B). Expression of ZsGreen was detected
in ERβ-ZsGreen lentivirus infected mammary gland tissues, indicating that ERβ-ZsGreen
was successfully expressed by the infected mammary gland cells (Fig. 10B). In order to
evaluate the infection efficiency, we performed the IHC staining for EGFP in mammary
gland tissues from the EGFP group and the ERα group. EGFP staining was observed in
over 50% of mammary epithelial cells in both groups, indicating that at least 50% of
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epithelial cells were infected by lentiviruses to overexpress ERα and the reporter EGFP
protein (Fig. 10C). These results demonstrated that rat mammary gland cells were
successfully infected in situ by lentiviruses to overexpress ERα or ERβ in mammary
epithelial cells.

Effect of ERα and ERβ Overexpression on Rat Mammary Cell Proliferation
Proliferating cells were labeled with BrdU and the mammary cell proliferation
rate was determined by BrdU-staining. Representative images of BrdU-labeled
proliferation cells in the mammary lobular and ductal structures are shown in Figure 9A
and 10A. As expected, overexpression of EGFP did not affect the cell proliferation rate in
both the proestrus and diestrus phases (Fig. 11B and 12B). Overexpression of ERα
significantly increased mammary epithelial cell proliferation rate in the lobular structure
but not in the ductal structure in the proestrus phase, and dramatically increased the
proliferation rate in both the lobular and ductal structures in the diestrus phase, supporting
the positive effect of ERα on cell proliferation during the estrous cycle (Fig. 11B and 12B).
The proliferation rate was increased about 1.2 times in the proestrus phase and about 1.8
times in the diestrus phase (Fig. 11B and 12B), indicating that after high level of estrogen
stimulation in the estrus phase, ERα significantly increased mammary cell proliferation
rate in the diestrus phase.
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In the ERβ group, overexpression of ERβ significantly decreased cell proliferation
rate in both lobular and ductal structures in the proestrus phase and decreased cell
proliferation rate in ductal structure in the diestrus phase, indicating that high levels of ERβ
can inhibit mammary cell proliferation in vivo (Fig. 11B and 12B). Furthermore, the
mammary epithelial cell proliferation rate was significantly lower in the ERβ group than
that in the ERα group in both lobular and ductal structures, indicating the distinct role of
these two types of ERs in regulation of cell proliferation during the estrous cycle (Fig. 11B
and 12B). Taken together, these data support that ERα overexpression promotes and ERβ
overexpression inhibits mammary epithelial cell proliferation in both the proestrus and
diestrus phases.

Effect of ERβ on Amphiregulin Expression
The epidermal growth factor (EGF) family member amphiregulin is an important
mediator of estrogen action (Ciarloni et al. 2007). Estrogen induces amphiregulin
expression and secretion via ERα, which activates EGFR signaling pathway to stimulate
cell proliferation (Visvader et al. 2003, Ciarloni et al. 2007, Kariagina et al. 2010). As
shown above, ERβ overexpression inhibits mammary cell proliferation, we wondered
whether ERβ inhibits mammary cell proliferation by suppressing amphiregulin expression.
To address this question, we quantified amphiregulin transcript levels in mammary gland
tissues overexpressing ERα and ERβ was quantified by RT-PCR. In the ERα group the
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expression level of amphiregulin increased about 1.5 fold in the proestrus phase (Fig. 13A)
and about 3.2 fold in the diestrus phase when compared to the uninfected EGFP group (Fig.
13B). In the ERβ group, the expression level of amphiregulin remained about the same as
that in the EGFP group in the proestrus phase (Fig. 13A) and slightly but not significantly
decreased in the diestrus phase (Fig. 13B). These data support that ERα induces mammary
cell proliferation by up-regulating amphiregulin expression. However, the inhibitory effect
of ERβ on mammary cell proliferation may involve downregulating amphiregulin
expression, but there are also other unknown mechanisms that are more responsible for the
inhibitory effect.
Discussion
Both ERα and ERβ are expressed in the mammary gland and therefore the
estrogen action in the mammary gland may be mediated by both types of estrogen receptors
(Couse et al. 1999, Hanahan et al. 2000, Harris et al. 2002, Berry et al. 2003, Herynk et al.
2004, Hartman et al. 2006, Mallepell et al. 2006, Tan et al. 2009). Although ERα and ERβ
share large homology, accumulating evidence from in vitro and in vivo studies suggests
that the two types of estrogen receptors may function differently (Harris 2007, Deroo et al.
2010, Warner et al. 2010). The expression of ERα differs from ERβ expression and their
expression level is tightly regulated in various estrogen regulated processes (Zhang et al.
2003). ERα expression has been demonstrated as the major regulatory node during normal
mammary gland development (Jensen et al. 2001). Previous studies on the expression of
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ERα showed ERα staining is detected in 10% to 40% of mammary epithelial cells and ERα
expression in mammary epithelial cells is detected only in proestrus phase of the estrous
cycle (Clarke et al. 1997, Saji et al. 2000, Cheng et al. 2004, Clarke 2004). ERβ expression
is found in epithelial cells and also some stromal cells (Palmieri et al. 2002, Schams et al.
2003). However, lack of studies on ERβ expression in vivo limited exploring the function
of ERβ in cell proliferation in mammary gland during estrous cycle.
In the present study, we investigated the expression of ERα and ERβ in the
mammary gland of rats during estrous cycle and provided more in vivo expression analysis
for further characterizing the function of ERβ in mammary gland. Consistent with previous
studies, we found that ERα existed in about 20% of mammary epithelial cells in the
proestrus phase, but was not detected in mammary epithelial cells in the diestrus phase.
Although ERα has been suggested to play a more important role in mammary gland
development, interestingly, we observed that much more epithelial cells expressed ER,
with more than 50% in the proestrus phase and 20% in the diestrus phase. Consistent with
many prior studies, we did not detect the existence of ERα in stromal cells in the rat
mammary gland, and a small fraction of stromal cells was detected with ER staining in
both the proestrus and diestrus phases. A number of studies have shown the existence of
ERβ in stromal cells, but little is known about whether the fraction of ERβ positive stromal
cells change during the estrous cycle (Palmieri et al. 2002, Speirs et al. 2002). In the present

146

studies, we did not observe significant difference of ERβ positive stromal cells in the
estrous cycle. The function of ERβ in the mammary stromal cells is not clear.
Epithelial cell proliferation rate in the mammary gland is highly regulated by
steroid hormones which undergo dynamic changes during the estrous cycle. The mammary
cell proliferation rates have been studied using different animal models and different
proliferation markers. The overall trend is similar where the rate is lower in the proestrus
phase and higher in the diestrus phase (Söderqvist et al. 1997, Navarrete et al. 2005).
However it is worth noting that the expression of both ERα and ERβ decreases from
proestrus to diestrus. Considering the stimulatory role of ERα on cell proliferation, it is
possible that the increase of proliferation rate in the diestrus phase may be due to the
decreased level of ERβ. Studies supporting this hypothesis have used breast tumors to show
that loss of ERβ would result higher proliferation rate in breast tumor (Zhao et al. 2003,
Girault et al. 2004, Gruvberger-Saal et al. 2007, Honma et al. 2008).
To further dissect the function of ERβ in regulation of mammary cell proliferation
during the estrous cycle, we overexpressed ERα and ERβ separately in the rat mammary
gland using lentivirus carrying target gene and the reporter gene. The expression of the
reporter and infection efficiency were quantified first to make sure that most mammary
gland cells were infected.
After establishing the ERα and ERβ in vivo overexpression system, we were able
to evaluate the effect of ERα and ERβ overexpression on epithelial cell proliferation in rat
147

mammary gland during the estrous cycle. Our data confirmed that overexpression of ERα
significantly increased mammary cell proliferation rate in both the proestrus and diestrus
phases, supporting the positive role of ERα in regulation of cell proliferation (Sicinski et
al. 1997, Liu et al. 2002, Mallepell et al. 2006). Moreover, overexpression of ERα has a
more dramatic stimulatory effect on cell proliferation in the diestrus phase, indicating that
ERα regulates cell proliferation in a ligand dependent manner due to high level of estrogen
stimulation in estrus phase.
Most studies on the effect of ERβ on cell proliferation have been carried out in
vitro and have suggested that ERβ is a negative regulator of cell proliferation (Lazennec et
al. 2001, Liu et al. 2002, Visvader et al. 2003, Paruthiyil et al. 2004, Helguero et al. 2005,
Song et al. 2012). In our previous studies, we provided the first in vivo evidence that
activation of endogenous ERβ can counteract the mitogenic effect of ERα in the mammary
gland (Song and Pan 2012). In the present study, we provided further in vivo evidence
showing that overexpression of ERβ significantly decreased cell proliferation rate in both
the proestrus and diestrus phases. These data support that mammary cell proliferation rate
is inversely correlated with ERβ expression level.
The growth factor amphiregulin is one of the most important estrogen action
mediators, which have been shown to be downstream of ERα in regulation of cell
proliferation in the mammary gland (Ciarloni et al. 2007). Consistently, we found that
amphiregulin transcript levels were significantly higher in ERα overexpressing mammary
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gland. However, we did not observe any significant difference in the quantities of
amphiregulin transcripts in mammary gland tissues overexpressing ER, suggesting that
unlike ERα, ERβ may not affect the production of amphiregulin directly. In chapter two of
this dissertation we have shown that cells with both activated ERα and ERβ contain lower
level of amphiregulin compared to cells with activated ERα alone. Collectively, our in vivo
animal model studies demonstrated that ER may counteract the proliferative effect of ERα
in mammary gland either by high levels of ER or by activation of endogenous ER. There
is also the possibility that the ratio of ERα/ERβ is critical for mammary gland cell
proliferation. In the proestrus phase, without high level of estrogen, the overall proliferation
rate is low. In the ERα group, due to the high ratio of ERα/ERβ, cell proliferation rate was
increased about 1.2 fold. In contrast, cell proliferation rate was decreased 1.4 fold in the
ERβ group. In the diestrus phase, the proliferation rate was increased 1.8 fold in the ERα
group and was decreased 1.6 fold in the ERβ group. It has been shown that ERα and ERβ
can form heterodimers which are able to bind DNA and regulate transcription (Cowley et
al. 1997). It is possible that the formation of ERα/ER heterodimers decreases the number
of ERα homodimers which results in lower transcription activity. In most breast tumors,
ERα expression is much higher than that in normal breast tissue and ER expression is
found to be decreased or completely lost, which indicates that the ratio of ERα/ERβ may
be critical in regulating cell proliferation not only in normal mammary cells but also in
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breast tumor cells (Zhao et al. 2003, Girault et al. 2004, Regan et al. 2006, GruvbergerSaal et al. 2007, Honma et al. 2008).
Previous studies have shown that cell death induced by tamoxifen in ERβ
positive breast tumors is significant higher than that in ERβ negative breast tumors (Honma
et al. 2008). Thus, the expression level of ERβ or the ratio of ERα/ERβ might be used as
biomarkers in breast cancer diagnosis and examination of the expression level of ERα and
ERβ may help determine appropriate treatments for different patients. In addition, both
ERα and ERβ can be served as the pharmaceutical targets to treat breast cancer. Due to the
inhibitory effect of ERβ on cell proliferation, specific agonists of ERβ may be potential
drugs for breast cancer.
As discussed above, we further characterized the expression pattern and the effect
of ERα and ERβ on epithelial cell proliferation in the mammary gland during estrous cycle.
We found that both ERα and ERβ expression levels are higher in the proestrus phase and
decreases in the diestrus phase. By overexpressing ERα and ERβ in the mammary gland in
vivo, we showed that ERα stimulates whereas ERβ inhibits epithelial cell proliferation in
the mammary gland in both the proestrus and diestrus phases, implicating the distinct
mechanism of the two types of estrogen receptors in regulating cell proliferation.
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1 MTMTLHTKΑSGMΑLLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPΑVYNYPEGΑΑY

rERα

1 MTMTLHTKΑSGMΑLLHQIQGNELEPLNRPQLKMPMERΑLGEVYVDNSKPΑVFNYPEGΑΑY

hERα

61 EFNΑΑΑΑΑNΑQ-----VYGQTGLPYGPGSEΑΑΑFGSNGLGGFPPLNSVSPSPLMLLHPPP

rERα

61 EFNΑΑΑΑΑΑΑΑGΑSΑPVYGQSSITYGPGSEΑΑΑFGΑNSLGΑFPQLNSVSPSPLMLLHPPP

hERα

116 QLSPFLQPHGQQVPYYLENEPSGYTVREΑGPPΑFYRPNSDNRRQGGRERLΑSTNDKGSMΑ

rERα

121 HVSPFLHPHGHQVPYYLENEPSΑYΑVRDTGPPΑFYRSNSDNRRQNGRERLSSSSEKGNMI

hERα

176 MESΑKETRYCΑVCNDYΑSGYHYGVWSCEGCKΑFFKRSIQGHNDYMCPΑTNQCTIDKNRRK

rERα

181 MESΑKETRYCΑVCNDYΑSGYHYGVWSCEGCKΑFFKRSIQGHNDYMCPΑTNQCTIDKNRRK

hERα

236 SCQΑCRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSΑGDMRΑΑNLWPSP

rERα

241 SCQΑCRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDLEGRNEMGTSGDMRΑΑNLWPSP

hERα

296 LMIKRSKKNSLΑLSLTΑDQMVSΑLLDΑEPPILYSEYDPTRPFSEΑSMMGLLTNLΑDRELV

rERα

301 LVIKHTKKNSPΑLSLTΑDQMVSΑLLDΑEPPLIYSEYDPSRPFSEΑSMMGLLTNLΑDRELV

hERα

356 HMINWΑKRVPGFVDLTLHDQVHLLECΑWLEILMIGLVWRSMEHPGKLLFΑPNLLLDRNQG

rERα

361 HMINWΑKRVPGFGDLNLHDQVHLLECΑWLEILMIGLVWRSMEHPGKLLFΑPNLLLDRNQG

hERα

416 KCVEGMVEIFDMLLΑTSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHI

rERα

421 KCVEGMVEIFDMLLΑTSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHI
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476 HRVLDKITDTLIHLMΑKΑGLTLQQQHQRLΑQLLLILSHIRHMSNKGMEHLYSMKCKNVVP

rERα

481 HRVLDKINDTLIHLMΑKΑGLTLQQQHRRLΑQLLLILSHIRHMSNKGMEHLYNMKCKNVVP

hERα

536 LYDLLLEMLDΑHRLHΑPTSRGGΑSVEETDQSHLΑTΑGSTSSHSLQKYYITGEΑEGFPΑTV

rERα

541 LYDLLLEMLDΑHRLHΑPΑSRMGVPPEEPSQSQLTTTSSTSΑHSLQTYYIPPEΑEGFPNTI
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181 NDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRRERCGYRLVRRQRSADEQLH
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136 NDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRRERCGYRIVRRQRSSSEQVH

hERβ

241 CAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVLISRPSAPFTEASMMMSLTK

rERβ

196 CLSKAKRNGGHAPRVKELLLSTLSPEQLVLTLLEAEPPNVLVSRPSMPFTEASMMMSLTK

hERβ

301 LADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMMGLMWRSIDHPGKLIFAPDL

rERβ

256 LADKELVHMIGWAKKIPGFVELSLLDQVRLLESCWMEVLMVGLMWRSIDHPGKLIFAPDL

hERβ

361 VLDRDEGKCVEGILEIFDMLLATTSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDA

rERβ

316 VLDRDEGKCVEGILEIFDMLLATTSRFRELKLQHKEYLCVKAMILLNSSMYPLASANQEA

hERβ

421 DSSRKLAHLLNAVTDALVWVIAKSGISSQQQSMRLANLLMLLSHVRHASNKGMEHLLNMK

rERβ

376 ESSRKLTHLLNAVTDALVWVIAKSGISSQQQSVRLANLLMLLSHVRHISNKGMEHLLSMK

hERβ

481 CKNVVPVYDLLLEMLNAHVLRGCKSSITGSECSPAEDSKSKEGSQNPQSQ

rERβ

436 CKNVVPVYDLLLEMLNAHTLRGYKSSISGSECSSTEDSKNKESSQNLQSQ

Figure 7. Amino acid sequence comparisons of human and rat ERα and human and
rat ERβ
The panel A shows the alignment of human ERα amino acid sequence with rat ERα
sequences. The panel B shows the alignment of human ERβ amino acid sequence with rat
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ERβ sequences. Identical and similar residues are shaded in black and gray, respectively.
Dashes indicate gaps introduced to maximize the alignment.
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Figure 8. Immunostaining of ERα and ER in the rat mammary gland.
The expression pattern of ERα was determined by IF staining (green fluorescence,
top panels). Cell nuclei were counterstained with DAPI (blue fluorescence). Images of ERα
staining and DAPI staining were overlaid to show the localization of ERα-staining cells
(middle panels). The expression pattern of ER was determined by IHC staining with DAB
as substrate to give brown color (bottom panels). In the proestrus phase, ERα staining was
detected in about 20% of epithelial cells; ER was expressed in more than 50% of epithelial
cells and ER staining was also detected in some stromal cells. In the diestrus phase, no
ERα staining was detected in mammary epithelial cells; ERβ was expressed in about 20%
of mammary epithelial cells and some stromal cells. Magnification, 400×.
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Figure 9. Co-immunostaining of ERα and EGFP in the 293FT cell
The expression of ERα was determined by IF staining (red fluorescence, top panels). The
expression of EGFP was evaluated directly under fluorescence microscopy. Both ERα and
EGFP were detected in all cells. Magnification, 400×.
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Figure 10. Immunostaining of EGFP and immunoblotting of EGFP and ZsGreen in
the mammary gland infected by Lentivirus.
(A) Mammary gland tissues from rats in different groups were analyzed by SDSPAGE and immunoblotting. Expression of EGFP using anti-EGFP antibody was detected
in the EGFP and ERα groups but not in the uninfected control and ERβ groups. (B)
Mammary gland tissues from different groups were analyzed by slot-blot and
immunoblotting. Protein lysate harvested from 293FT cells infected by ERβ-ZsGreen
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lentivirus was used as positive control (pos. ctrl). Expression of ZsGreen using antiZsGreen antibody was detected in the ERβ group but not in any control and ERα groups.
(C) Representative EGFP IHC staining images of lobular and ductal structures in the
mammary gland in the EGFP group. Over 50% of mammary epithelial cells showed
intensive staining.
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Figure 11. ERα stimulates and ERβ inhibits mammary cell proliferation in the
proestrus phase.
(A) Representative images showing BrdU-labeled proliferation cells in the
mammary lobular and ductal structures of different groups of rats. BrdU-labeled cells were
detected by IHC staining with DAB as substrate to give brown color. Magnification, 400
×. (B) Percentage of BrdU-labeled proliferation cells in the mammary gland of different
groups of rats. Mammary epithelial cells in lobular and ductal structures were counted
separately, and the total is the combination of lobular and ductal cells. The p values of
comparison between two groups for the lobular structure are in table below
P value

Lobular

ERα vs EGFP

0.012

ERβ vs EGFP

0.002

ERα vs ERβ

<0.0001

Ductal

Total

0.0083

0.0006

0.0071

0.0002
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Figure 12. ERα stimulates and ERβ inhibits mammary cell proliferation in the
diestrus phase.
(A) Representative images showing BrdU-labeled proliferation cells in the
mammary lobular and ductal structures of different groups of rats. BrdU-labeled cells were
detected by IHC staining with DAB as substrate to give brown color. Magnification, 400
×. (B) Percentage of BrdU-labeled proliferation cells in the mammary gland of different
groups of rats. Mammary epithelial cells in lobular and ductal structures were counted
separately, and the total is the combination of lobular and ductal cells. The p values of
comparison between two groups for the lobular structure are in table below:
P value
ERα vs EGFP

Lobular

0.0005 <0.0001

ERβ vs EGFP
ERα vs ERβ

Ductal
0.002

<0.0001

<0.0001

Total
0.0002
0.0225
<0.0001
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Figure 13. ERα increases amphiregulin expression in the mammary gland.
RNA levels of amphiregulin were determined by quantitative real-time RT-PCR.
β-actin was used as internal control. In the proestrus phase, the expression levels of
amphiregulin were similar in the Control, EGFP and ERβ groups (figure 5 A). In the ERα
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group the expression of amphiregulin was increased about 1.5 fold (figure 5 A). In the
diestrus phase, amphiregulin expression in the ERα group was significantly higher than
that in the Control and ERβ group (figure 5 B). The p values are as follows: 0.013 for ERα
vs. EGFP; 0.014 for ERα vs. ERβ (*p < 0.05).
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CHAPTER 4: Summary and Discussion

Expression of estrogen receptors in the Mammary Gland
The expression levels of estrogen receptors have been shown to be an important
mechanism for regulating mammary cell proliferation under different physiological
conditions (Clarke et al. 1997, Saji et al. 2000, Cheng et al. 2005). Abnormal expression
of ERα and ERβ may induce tumorigenesis (Frech et al. 2005, Regan et al. 2006). Clinical
studies have demonstrated that about 70% of breast tumors are ERα positive and most of
them have high level of ERα compared with normal breast tissues (Shoker et al. 1999,
Shaaban et al. 2002). On the contrary, ER expression is found decreased or lost in many
primary breast tumors (Zhao et al. 2003, Girault et al. 2004, Gruvberger-Saal et al. 2007,
Honma et al. 2008). Therefore it is important to characterize the expression of estrogen
receptors in different stages and understand how the expression of estrogen receptors is
regulated in different physiological environment.
The ovariectomised (OVX) animals are often used as a model for estrogen
deficiency or postmenopausal research. The percentage of ERα positive cells increases in
OVX rats, presumably due to decreased level of circulatory estrogens (Berry et al. 2003,
Song et al. 2012). In chapter two of this dissertation, we investigated the expression of ERα
and ERβ in the mammary gland of OVX rats. ERα was detected in more than 50% of
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luminal epithelial cells. Compared with that of the ovary-intact rats, the mammary gland
of OVX rats showed more cells with ERα expression but the staining intensity was weaker.
ER was detected in almost all mammary epithelial cells with strong staining, and ER
staining was also detected in some stromal cells in the mammary gland. These results
demonstrate that both ERα and ERβ are expressed in significantly more cells in the lowestrogen in vivo environment and further support the downregulating effect of estrogen on
the expression of estrogen receptors.
Estrous cycle is controlled by systemic hormones such as estrogen and
progesterone (Jones et al. 2006). In the normal mammary gland, the expression of estrogen
receptors is regulated by these hormones during estrous cycle (Clarke et al. 1997, Cheng
et al. 2004). However, most of these studies have been focusing on the expression of ERα,
the expression of ERβ during estrous cycle is much less studied. It is generally believed
that ERα is expressed in about 10-40% mammary epithelial cells but not expressed in
stromal cells (Clarke et al. 1997, Clarke 2004). ERα reaches the peak of expression in the
proestrus phase of the estrous cycle and is then quickly degraded due to peak level of
estrogen in the estrus phase (Saji et al. 2000, Cheng et al. 2005). ER is expressed not only
in luminal epithelial cells but also in some stromal cells and myoepithelial cells (Palmieri
et al. 2002). The studies by Schams et al. (2003) demonstrated that approximately 70% of
epithelial cells express ER throughout all developmental phases.
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In chapter three of this dissertation, we evaluated the expression of ERα and ERβ
in normal rat mammary gland tissues during the estrus cycle. It is known that estrogen level
gradually increases in the proestrus phase, reaches the peak in the estrus phase, remains at
high level for most of the diestrus phase (Clarke et al. 1997, Cheng et al. 2004). Consistent
with results from most previous studies, we found that in the proestrus phase, ERα was
expressed in about 20% of mammary epithelial cells, and in the diestrus phase, no ERα
staining was detected in mammary epithelial cells. ER was expressed in more than 50%
of mammary epithelial cells and some stromal cells in the proestrus phase. There were still
20% of epithelial cells and a fraction of stromal cells expressing ERβ in the diestrus phase,
although the percentage dropped significantly and the staining intensity of ERβ was weaker
compared to the proestrus phase. These results indicate that the expression of both ERα
and ERβ undergoes dynamic changes during the estrous cycle, higher before the peak of
estrogen in the estrous phase and significantly decreased after estrogen spikes.

Function of Estrogen Receptors in Mammary Gland Development
Estrogen is involved in regulating the growth and differentiation of many tissues,
including the mammary gland, the fallopian tube and the uterus; the function of estrogen
is mediated by two types of estrogen receptors, ERα and ERβ (Bocchinfuso et al. 1997,
Cooke et al. 1997, Russo et al. 1999, Shao et al. 2007). In the mammary gland, ERα is
known as the primary estrogen receptor and well characterized as a positive regulator of
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cell proliferation (Bocchinfuso et al. 1997). In contrast to the well-established role of ERα,
ERβ is much less studied and the function of ERβ in mammary cell proliferation is still
debatable (Lazennec et al. 2001, Visvader et al. 2003, Cheng et al. 2004, Paruthiyil et al.
2004, Strom et al. 2004).
In this dissertation, we used two approaches to investigate the function of ERβ in
the mammary gland. In the first approach, endogenous ERα and/or ERβ in OVX rats were
selectively activated using ERα and/or ERβ selective agonists (Chapter 2). We found that
endogenous ERα activation stimulates cell proliferation whereas endogenous ERβ
activation counteracts the proliferative effect of ERα in the mammary gland (Chapter 2).
In the second approach (Chapter 3), rat mammary gland was infected with lentiviruses to
overexpress ERα or ERβ to determine the effect of expression level of ERα or ERβ on
mammary cell proliferation. Overexpressing ERβ in the mammary gland of mature virgin
rats decreased cell proliferation rate in both proestrus and diestrus phases, further
supporting that ERβ, unlike ERα, is a negative regulator of mammary cell proliferation.
The effects of estrogen receptors on cell proliferation are similar in the ductal and lobular
structures in both OVX rats and mature virgin rats. Collectively, these data support that in
contrast to ERα, ERβ is able to inhibit mammary cell proliferation.
Both ERα and ERβ belong to the nuclear receptor superfamily of transcription
factors and share similar structures, accumulating evidence indicates that they have distinct
functionalities (Heldring et al. 2007). Estrogen receptors regulate gene transcription by
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binding to estrogen response elements (EREs) in the promoters of target genes and utilizing
AF-1 and AF-2 domains to recruit coregulators. Therefore the trans-acting function of
estrogen receptors is highly dependent on AF1 and AF2 domains in a cell-type and
promoter-dependent manner (Matthews et al. 2003). The high degree of sequence
divergence of AF domains suggests that ERα and ER can recruit different co-regulators,
hence regulate gene expression differently (Cowley et al. 1997, Hall et al. 1999). When
comparing the activity of AFs in the two types of estrogen receptors, it has been noticed
that AF-1 in ERα is very active, while under the same condition, the AF-1 domain of ERβ
only has negligible activities (Barkhem et al. 1998). The amphiregulin gene has a putative
ERE and amphiregulin is an essential mediator of ERα mitogenic activity (Britton et al.
2006, Ciarloni et al. 2007, Kariagina et al. 2010). In chapter three of this dissertation, we
observed that amphiregulin transcript level was induced by overexpression of ERα but not
by ERβ, which may be due to the relative lack of active AF-1 activity of ERβ. It has been
shown that alteration of the AF-1 domain can enable ERβ to respond to anti-estrogens
(McInerney et al. 1998).
Besides directly binding to ERE and recruiting coregulators to regulate gene
transcription, estrogen receptors can modulate the activity of the AP-1 protein and
stimulating protein 1 (Sp1) (Webb et al. 1999, Saville et al. 2000, Hall et al. 2001). Upon
estrogen stimulation, ERβ inhibits while ERα activates AP-1-mediated transcription
(Webb et al. 1999, Kushner et al. 2000). The estrogen-ERα complex binds to sequences
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containing the AP1 site or cAMP response element (CRE) to promote cyclin D
transcription (Liu et al. 2002). In chapter two of this dissertation, we found that cyclin D1
was induced by ERα selective agonist PPT and PPT-induced cyclin D1 expression was
suppressed by ERβ selective agonist DPN.
In chapters two and three of this dissertation, we showed that that the level of
estrogen and the expression level of ERα are critical for mammary cell proliferation. Under
the condition of low level of estrogen in proestrus phase or in OVX rats, few ERα
molecules are activated and the proliferation rate keeps at a lower level. After high level of
estrogen stimulation in estrus stage or PPT activation, activated ERα stimulates target gene
expression and promotes cell proliferation in diestrus phase and in the PPT group.
By investigating the relationship between the expression level of ERα, ERβ and
the proliferation rate, it is possible that the ratio of ERα/ERβ might be involved in
regulating mammary cell proliferation. ERα and ERβ co-expressed in mammary cells
could form homodimers or heterodimers to regulate gene expression in the nucleus upon
estrogen activation, and the ratio of ERα/ERβ might be critical for the formation of ER
dimers. (Pettersson et al. 1997, Nilsson et al. 2001, Heldring et al. 2007). It is postulated
that the higher ratio of ERα/ERβ, the more ERα/ERα homodimers are formed to promote
cell proliferation in the mammary gland. In contrast, more ERβ/ERβ homodimers will be
formed when the ratio of ERα/ERβ is lower, leading to reduced cell proliferation.
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ERα/ERβ heterodimer could also be formed in ERα and ERβ co-expressing cells,
and its binding affinity to ERE was shown similar to the homodimer (Cowley et al. 1997).
However, the way it regulates cell proliferation is much more complicated. In the OVX
rats, PPT and DPN activated ERα and ERβ respectively. Treatment with PPT and DPN
simultaneously activated both ERα and ERβ and resulted in a proliferation rate higher than
that in the untreated control group but lower than that in the PPT treated group, indicating
that ERβ activated by DPN is able to partially block the function of ERα via the formation
of heterodimers (Chapter 2).
Chapter 3 shows that in the proestrus phase of normal mammary gland, although
the ratio of ERα/ERβ was relatively high, due to lack of estrogen stimulation, the
proliferation rate was low. However, in the mammary gland overexpressing ERβ, due to a
lower ratio of ERα/ERβ, the proliferation rate in the proestrus phase was even lower than
that in the control group. In contrast, the mammary gland overexpressing ERα had a higher
ERα/ERβ ratio and also a higher proliferation rate. In the diestrus phase, the high ERα/ERβ
ratio might account for the high cell proliferation rate in the ERα overexpressing group;
whereas the low ERα/ERβ ratio might account for the reduced cell proliferation rate in the
ERβ overexpressing group. In addition, the high ratio of ERα/ERβ in most breast tumors
corresponds to a much higher proliferation rate than that in the normal breast tissues (Zhao
et al. 2003, Girault et al. 2004, Gruvberger-Saal et al. 2007, Honma et al. 2008). All these
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data support the hypothesis that the mammary cell proliferation rate is controlled largely
by the ratio of ERα/ERβ.

Function of ERα and ERβ on cell proliferation in the uterus, colon, and lung
Besides the mammary gland, estrogens are also involved in the development of
many other tissues. As one of the major classical estrogen target tissues, the uterine growth
and differentiation is regulated by estrogens (Cooke et al. 1997, Tan et al. 1999). Increasing
evidence suggested that estrogens are also important in lung and colon development,
physiology, and even carcinogenesis (Adami et al. 1989, Arai et al. 2000, Omoto et al.
2001, Rossouw et al. 2002, Townsend et al. 2012). However the expression and effect of
estrogen receptors in these tissue are not fully understood. In order to evaluate the effect of
estrogen receptors in these organs, we used ER selective agonists to activate ERα and ERβ
in OVX rats.
The effects of estrogen in the uterus are mainly mediated by ERα which is the
predominant type of estrogen receptor expressed in the uterus (Li 1994). We found that in
the uterus of the OVX rats, ERα was detected in almost all endometrial luminal epithelial
cells, glandular epithelial cells, and stromal cells and the staining intensity in the epithelial
cells was much stronger than that in the stromal cells. Consistent with other studies,
treatment with ERα-selective agonist PPT increased uterine diameter, uterine wet weight
(UWW) and the cell proliferation rate (Couse et al. 1999, Persson et al. 1999, Harris et al.
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2002, Frasor et al. 2003, Tilli et al. 2003, Hartman et al. 2006, Wegorzewska et al. 2008).
The uterus morphology and cell proliferation rate in the PPT group were very similar to
that of the estrogen group, confirming that ERα predominately mediates estrogen action in
the uterus. In contrast, the uterus morphology, weight and cell proliferation rate in the ERselective agonist DPN treated group were very similar to that of the control group,
indicating that ER had little effect on the estrogenic activity in the uterus. In addition, coadministration of DPN with PPT did not inhibit PPT’s effect on uterine wet weight and cell
proliferation rate, demonstrating that DPN had little effect on the estrogenic activity of PPT
in the uterus. This is different from the suppressive effect of DPN on PPT in the mammary
gland (Persson et al. 1999, Harris et al. 2002, Berry et al. 2003, Frasor et al. 2003, SánchezCriado et al. 2004, Wegorzewska et al. 2008, Bliedtner et al. 2010). The different effects
of DPN on PPT in the mammary gland and the uterus may be due to differential expression
levels of ERβ or different ratios of ERα/ERβ in these two types of tissues. ER expression
is more widespread than ERα in the mammary gland; whereas ERα expression is more
prevalent in the uterine endometrium.
Confliciting results have been reported on the effects of estrogens on colon growth.
Some studies showed that estrogens inhibit cell proliferation while others demonstrated
that estrogens promote the proliferation of colon cells (Hoff et al. 1980, Xiaomeng et al.
1994, Calle et al. 1995, Newcomb et al. 1995, Di Domenico et al. 1996, Franceschi et al.
1998, Rossouw et al. 2002, Anderson et al. 2004). Although conflicting results have also
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been obtained from studies on the expression of ERα, it has been widely agreed that ERβ
is the predominant estrogen receptor in the colon and can be detected in both the normal
colon epithelium and colorectal carcinomas (Sutter et al. 1996, Waliszewski et al. 1997,
Arai et al. 2000, Foley et al. 2000, Campbell-Thompson et al. 2001, Martineti et al. 2005).
In the colon tissues of the OVX rats, we did detect the expression of ERβ but we
did not detect ERα staining. Our data demostrated that activation of ERα and ERβ by PPT
and DPN respectively has no effect on the cell proliferation rate in the colon tissues of the
OVX rats (Appendix A).
Estrogens have been illustrated to stimulate lung cell proliferation in normal lung
fibroblasts, suggesting that estrogen may also be involved in lung development (Omoto et
al. 2001, Townsend et al. 2012). Consistent with previous studies, we did not observe ERα
expression in the lung tissues of the OVX rats (Matsuda et al. 1993, Ollayos et al. 1994,
Brown et al. 1997, Nunno et al. 2000, Patrone et al. 2003, Morani et al. 2008). ERβ staining
was detected in the lungs of the OVX rats, indicating that ERβ may be the predominant
estrogen receptor in the lung. Many studies suggested that ERβ is involved in the growth,
development, or tumorigenesis of the lung (Omoto et al. 2001, Patrone et al. 2003). In
Appendix B, we showed that the precentages of BrdU labeled cells were similar among
different treatment groups, indicating that ERα and ERβ activated by selective agonists
have no effect on cell proliferation in lung tissues of the OVX rats.
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Potential medical use of ERβ in hormone replacement therapy and breast cancer
treatment
In this dissertation, we evaluated the effect of ERβ on cell proliferation in both
mature virgin rats and OVX rats. Our data supports that ERβ is a negative regulator of
mammary gland growth and the ERα-mediated estrogenic activities in the mammary gland
can be suppressed by ER. These findings suggest that ERβ could be served as the
pharmaceutical target to design new hormone replacement therapy regimens for
postmenopausal syndromes and new drugs to treat breast cancer. In chapter two of this
dissertation, we found that PPT has similar activities as estrogen in the mammary gland
and uterus and that the adverse effect of PPT mediated estrogenic activities in the
mammary gland can be opposed by DPN, indicating that PPT can be used as alternative to
estrogen and we can use PPT and DPN together to reduce the side effects in hormone
replacement therapy.
In the OVX rats, we also evaluated the cell proliferation rate in the uterus, colon
and lung tissues. We found that compared with the estrogen regimen, the PPT and DPN
combined regimen is able to decrease the mammary cell proliferation rate, which reduces
the risk of breast cancer. Moreover, the PPT and DPN regimen does not increase cell
proliferation rate in lung and colon tissues, indicating that this regimen has no adverse
effect on these tissues.
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The estrogen and progesterone regimen has been observed to increase mammary
cell proliferation much higher than estrogen alone, but the estrogenic activity of estrogen
in the uterus can be opposed by progesterone (Grady et al. 1995, Persson et al. 1999, Ross
et al. 2000). We showed that in the OVX postmenopausal rats, compared with the PPT and
progesterone regimen, the PPT, DPN and progesterone regimen decreased cell
proliferation in the mammary gland, which increased the risk of breast cancer. Moreover,
the PPT, progesterone and DPN regimen does not increase cell proliferation rate in lung
and colon tissues, indicating that this regimen has no adverse effect on these tissues. Thus,
the PPT/DPN or PPT/DPN/Progesterone regimen may be a good option for hormone
replacement therapy.
In this dissertation, we only assessed the effect of different estrogen alternatives
on cell proliferation and hence the risk of cancer. There are still questions to be answered
for the proposed PPT/DPN regimen for HRT. First, we have to show that the beneficial
effects of estrogen or progesterone are not abolished by PPT or DPN. We have shown that
in the uterus, DPN did not increase cell proliferation rate in the presence of progesterone,
indicating that the beneficial effect of progesterone in the uterus was not abolished by DPN.
PPT and DPN have been shown to prevent hot flashes (Harris et al. 2002, Bowe et al. 2006).
PPT has also been proved to prevent loss of bone mineral density (Harris et al. 2002). Both
estrogen and DPN are able to decrease depression and anxiety-like behaviors (Lund et al.
2005, Walf et al. 2008). These studies suggest that PPT and DPN preserve the beneficial
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effects of estrogen on many aspects of postmenopausal symptoms. Another concern is that
whether this new regimen has adverse effect in other tissues. Estrogen is an important
systemic hormone, targeting on different systems and tissues including reproductive
system, cardiovascular system, brain and bone (Massaro et al. 1996, McEwen et al. 1999,
Kleerekoper 2001, Jones et al. 2006). Although we have demonstrated that this new
regimen did not have adverse effect in the lung, colon and uterus tissues, further studies
are needed to determine the effect of this regimen in other estrogen targeted tissues.
ERα selective antagonists such as tamoxifen and raloxifene have been used to
treat breast cancer. According to the results of our study and other studies, ERβ agonist
DPN suppressed the estrogenic effect in the mammary gland and thus may also be
potentially used to treat breast cancer (Paruthiyil et al. 2004, Ström et al. 2004, Honma et
al. 2008, Song et al. 2012). Besides DPN, more ERβ selective agonists have been
discovered and all these agonists may be potential new drugs for the prevention and
treatment of breast cancer (Harris et al. 2003, Malamas et al. 2004, Hughes et al. 2008).
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Appendix A
The effects of ER agonists on colon cell proliferation
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OVX rats were administered by i.p. injection once a day for three consecutive
days with DMSO (control), DPN, PPT, PPT and DPN (PPT/DPN), respectively. BrdU was
injected concurrently with each drug administration to label proliferating cells. (A)
Representative microimages showing BrdU-labeled proliferation cells in the colon from
different groups of rats. BrdU labeled cells were detected by IHC staining with DAB as
substrate to give brown color. Magnification, 400×. (B) Percentage of BrdU-labeled
proliferation cells in the colon of different groups of rats. The proliferation rate is similar
among different treatment groups.
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Appendix B
The effects of ER agonists on lung cell proliferation
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OVX rats were administered by i.p. injection once a day for three consecutive
days with DMSO (control), DPN, PPT, PPT and DPN (PPT/DPN), respectively. BrdU was
injected concurrently with each drug administration to label proliferating cells. (A)
Representative microimages showing BrdU-labeled proliferation cells in the lung from
different groups of rats. BrdU labeled cells were detected by IHC staining with DAB as
substrate to give brown color. Magnification, 400×. (B) Percentage of BrdU-labeled
proliferation cells in the lung of different groups of rats. The proliferation rate is similar
among different treatment groups.
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